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POPULAR SCIENCE SUMMARY OF THE THESIS 
Anabolic hormones such as testosterone and growth hormone could be beneficial for physical 
performance. The second to fourth digit ratio, suggested as a measurement of testosterone 
exposure during fetal life, has also been related to athletic ability. There is however a lack of 
knowledge on how the body’s own anabolic hormones and the digit ratio may affect muscle 
mass and physical performance in female elite athletes. In doping tests, the level of steroid 
hormones, for example testosterone, is measured in urine. In men, genetic variations have been 
shown to affect the steroid hormone levels. However, it is not known if genetic variations and 
hormonal contraceptives affect the steroid hormone levels in urine in female elite athletes.  
The purpose of this thesis was to study the body’s own anabolic hormones and the digit ratio 
in female Olympic athletes compared to untrained controls and to evaluate possible 
relationships with body composition and physical performance in the Olympic athletes. We 
also aimed to examine if genetic variations and hormonal contraceptives alter the steroid 
hormone levels in urine and if these hormone levels were different between athletes and 
controls.  
We found relatively higher levels of anabolic hormones and a lower digit ratio (higher exposure 
to testosterone during fetal life) in the female Olympic athletes. The anabolic hormones were 
associated with increased muscle mass, stronger bone tissue and better physical performance. 
A low digit ratio was related to steroid hormone levels in urine but not to hormone levels in 
blood. The steroid hormone levels in urine were lower in the athletes than the controls and both 
genetic variations and hormonal contraceptives affected these hormone levels.  
In conclusion, these findings reflect that the body’s own anabolic hormones are important for 
muscle mass and physical performance in female Olympic athletes. This knowledge is valuable 
for the ongoing discussion about hyperandrogenism in female athletes. Based on the digit ratio 
hormonal exposure during fetal life appears to be associated with athletic performance. 
Furthermore, the association between the digit ratio and levels of steroid hormones in urine can 
be related to how these steroid hormones are processed in the body. Both genetic variations 
and hormonal contraceptives resulted in differences in steroid hormone levels in urine. The 
higher levels of these hormones in untrained women compared to Olympic athletes can be a 






POPULÄRVETENSKAPLIG SAMMANFATTNING  
Anabola hormoner såsom testosteron och tillväxthormon har uppbyggande effekter på 
muskelmassa och anses kunna öka den fysiska prestationsförmågan. Även fingerkvoten 
(längden på pekfingret delat med längden på ringfingret) som har lagts fram som mått på 
hormonmiljön under fosterlivet, har kopplats till prestation. Det saknas dock kunskap om hur 
kroppsegna anabola hormoner och fingerkvoten påverkar kroppssammansättning och fysisk 
prestation hos elitidrottande kvinnor. Vid dopingtest utvärderar man steroidhormoner, 
exempelvis testosteron, i urinprover. Tidigare studier på män har visat att det finns genetiska 
variationer som påverkar urinsteroidhormonnivåerna. Andra faktorer som kan påverka 
tolkningen av dopingtester är hormonella preventivmedel. Det är inte kartlagt hur genetiska 
variationer och hormonella preventivmedel påverkar urinsteroidprofilen hos kvinnliga 
elitidrottare.  
Målet med denna avhandling var att studera kroppsegna anabola hormoner och fingerkvoten 
hos kvinnliga Olympiska idrottare och otränade kontroller, samt utvärdera eventuella 
kopplingar till kroppsammansättning och fysisk prestation hos kvinnliga Olympier. Vi hade 
även som syfte att studera om genetiska variationer och hormonella preventivmedel påverkar 
nivåerna av steroidhormon i urinen hos kvinnor och om dessa hormonnivåer skiljer sig åt 
mellan de kvinnliga Olympiska idrottarna och kontrollgruppen.  
Vi fann högre nivåer av anabola hormoner och en lägre fingerkvot (mer påverkan av manliga 
könshormon under fosterlivet) hos de kvinnliga Olympiska atleterna. Dessa anabola hormoner 
var relaterade till ökad muskelmassa och ökad bentäthet samt bättre fysisk prestation. En lägre 
fingerkvot hade samband med högre nivåer av vissa steroidhormon i urin, men inte till 
hormonnivåer i blod. Nivåerna av steroidhormoner i urin var högre hos kontrollerna än de 
kvinnliga Olympiska atleterna och hos de sistnämnda var en högre träningsnivå relaterat till 
lägre urinsteroidhormonnivåer. Både genetiska variationer och hormonella preventivmedel 
påverkade urinsteroidhormonnivåer.  
Sammanfattningsvis talar dessa resultat för att kroppsegna anabola hormoner spelar roll för 
ökad muskelmassa och fysisk prestation hos kvinnliga Olympiska idrottare. Denna kunskap är 
viktig för den pågående diskussionen om hyperandrogenism hos kvinnliga idrottare. Baserat 
på fingerkvoten, förefaller hormonmiljön under fosterstadiet ha samband med fysisk prestation 
och hormonnivåer i urin. Det senare talar för att fingerkvoten har en koppling till hur 
steroidhormoner omsätts i kroppen. Både genetiska variationer och hormonella preventivmedel 
påverkade urinsteroidprofilen hos kvinnor. Att otränade kontroller utsöndrar högre nivåer av 
androgener i urin kan hypotetiskt bero på att elitidrottskvinnor har ökad androgen utsöndring 




Endogenous androgens and insulin-like growth factor-I (IGF-I) are anabolic hormones that 
may contribute to increased muscle mass and possibly enhanced athletic performance. 
Furthermore, the second to fourth digit ratio (2D:4D ratio), suggested as an indirect 
measurement of prenatal androgen exposure, has been related to athletic ability. However, there 
is limited knowledge on the role of endogenous anabolic hormones for body composition and 
physical performance in female Olympic athletes. Moreover, the 2D:4D ratio has not been 
studied in relation to serum and urinary androgens and athletic performance in female elite 
athletes. In men, there are known genetic variations in genes coding for androgen metabolizing 
enzymes that affect the urinary androgen profile evaluated in doping tests. For women, less is 
known concerning the impact of genetic variations on the urinary androgens. In addition, the 
effects of hormonal contraceptive use on urinary steroid levels need to be investigated further.  
The aim of this thesis was to evaluate the anabolic hormonal profile and the 2D:4D ratio in 
female Olympic athletes compared to untrained controls and in relation to body composition 
and physical performance. In addition, we aimed to investigate the relationship between the 
2D:4D ratio and serum and urinary androgens. Furthermore, we studied the impact of hormonal 
contraceptives and genetic variations on the urinary steroid profile in female elite athletes and 
compared the urinary steroid between female athletes and controls.  
In this cross-sectional study, including female Olympic athletes (n=106) and age- and BMI 
matched untrained controls (n=117), we found significantly higher precursor androgens 
dehydroepiandrosterone (DHEA), androstenediol (5-DIOL) as well as IGF-I, age-adjusted 
IGF-I and insulin-like growth factor binding protein-1 (IGFBP-1) in the athletes compared to 
controls. The 2D:4D ratio was significantly lower in the athletes indicating higher exposure to 
androgens during fetal life. The precursor androgens, IGF-I and IGFBP-1 were related to 
increased muscle mass and lower fat percentage. In the athletes, precursor androgens, 
dihydrotestosterone (DHT), IGF-I, IGFBP-1 and the 2D:4D ratio were associated with better 
performance in physical fitness tests. In addition, the 2D:4D ratio was associated with urinary 
androgens but not serum androgens. The controls excreted significantly higher concentrations 
of urinary androgen metabolites compared to the athletes, however serum androgens were 
comparable or higher among the athletes. For the athletes, training hours per week were 
negatively associated with some urinary androgens. Moreover, we found that genetic variations 
in UGT2B17 and CYP17A1 and hormonal contraceptive use had a significant impact on the 
urinary steroid profile in women. 
In conclusion, endogenous anabolic hormones are associated with an anabolic body 
composition and enhanced physical performance in female Olympic athletes. Prenatal 
androgen exposure may also be of importance for athletic capacity in female Olympic athletes 
and possibly reflect androgen metabolism, since the 2D:4D ratio was associated with urinary 
androgen metabolite concentrations. Both genetic variations in UGT2B17, CYP17A1 and 
hormonal contraceptive use affects the urinary androgen levels in women. Our finding of 
higher urinary androgen concentrations in controls compared to the athletes and the negative 
association between training hours and urinary androgens is hypothetically due to increased 
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Sport has been a part of society since the prehistoric age, for instance one of the most important 
sporting competitions today, the Olympic Games, originated in Greece around 3000 years ago. 
In 1900 women were allowed to compete in the Olympic games and since then the percentage 
of women participating has increased from 2.2 % to an expected 48.8 % in the Tokyo 2020 
Games (1). As for endocrinology, diseases related to hormonal pathologies have been evident 
throughout history, however, the term hormone (from the Greek “excite”) was introduced as 
late as 1905 (2) and it took until the 1940s before androgen synthesis was defined in women 
(3). With this in mind, it is not surprising that much remains to be clarified within the field of 
sports endocrinology for female athletes.  
Having been born into a family that includes Olympic athletes, an Olympic gold medal winner, 
researchers, medical doctors and sports enthusiasts, one can wonder if it was nature or nurture 
that lead me to become an elite volleyball player and earn a medical degree. I took an early 
interest in sports endocrinology and when given the chance to start my PhD in Professor 
Angelica Lindén Hirschberg’s group, I knew I was in the right place. The past six years of 
research have resulted in a thesis focusing on endogenous anabolic hormones relation to body 
composition and physical performance in female Olympic athletes. I also studied factors that 
may affect the urinary steroid profile and consequently be important for doping interpretation.  
The research process has been a journey of both despair and success. I have suffered from 
classic writer’s block and constantly questioned my research findings to the point of 
exhaustion. But through hard work and determination I have also won research awards and 
scholarships and been fortunate to present my research at congresses and in peer-reviewed 
journals. None of this would have been possible without committed supervisors, great 
colleagues and the support of the athletic community, family and friends. Hopefully, the results 
presented in this thesis will inspire future researchers and society in general in their effort to 
contribute and continue supporting research in sports endocrinology.  
 
 





Androgens and growth factors such as testosterone (T) and insulin-like growth factor-I (IGF-
I) are anabolic hormones, that may contribute to increased muscle mass and enhanced physical 
performance in athletes (4, 5). In men, the positive anabolic effects of endogenous androgens 
for physical performance are well established (4, 6). However, there is limited understanding 
of the role of endogenous anabolic hormones for body composition and physical performance 
in elite female athletes.  
Over the last decade there has been an ongoing debate within the sporting community about 
the possible performance enhancing effect of endogenous anabolic hormones in the female 
athlete. Historically, in the majority of elite sports events, competitors have been divided 
according to gender due to the difference in physical performance between men and women 
(7). Recently circulating T was proposed as the most important factor explaining the sex 
difference in athletic performance (4). Therefore, in 2011, the International Associations of 
Athletics Federations, and in 2012 the International Olympic Committee (IOC) implemented 
regulations on female hyperandrogenism in sports related to rare disorders of sex development 
(DSD). In summary it was stated that female athletes with endogenous testosterone levels in 
the male range and functioning androgen receptors (AR) were not eligible to compete in female 
sports events. These rules were intended to ensure fairness in women’s elite sporting 
competition and not to determine sex or gender in the athlete (4, 8). Supporters argued that 
circulating T levels, in the male range (approximately fifteen times higher), clearly imply an 
advantage for physical performance (4, 8-11). However, critics have highlighted a lack of 
scientific data supporting these claims as well as other possible factors that may explain the 
differences in physical performance (12-14). The current knowledge about the anabolic effects 
of T in women was mainly derived from animal studies, investigations including only men or 
case reports and the Deutsche Demokratische Republic (DDR) records of the effects of 
anabolic steroids (i.e. doping) in female athletes (4, 15). Athletes affected by these regulations 
appealed to the Court of Arbitration of Sport (CAS), resulting in the regulations being 
suspended in 2015 pending further scientific evidence of the role of endogenous anabolic 
hormones in athletic performance in women. Since then, new scientific evidence has been 
published and reviewed by CAS, resulting in updated regulations being adopted in 2018.  
When starting this PhD in 2015 there were only two publications on endogenous T and physical 
performance in female athletes. One by Cardinal and Stone (16) including 22 female athletes, 
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reporting a positive relation between circulating T and counter-movement jump (CMJ) 
performance. The second by Crewther and Christian (17), found no correlation between T 
levels and performance, however this study only included 4 female athletes. In 2017, study I 
included in this thesis was published providing scientific results on the relation between 
endogenous androgens, body composition and physical performance in female Olympic 
athletes. More data demonstrating a positive effect by androgens on physical performance in 
women was later published (8, 18, 19). In an effort to explore other possible factors important 
for athletic performance in women we continued by investigating endogenous IGF-I and 
insulin-like growth factor binding protein-1 (IGFBP-1) (study III) and the second to fourth digit 
ratio (2D:4D ratio) (study II), and their relationships with physical performance and body 
composition in female Olympic athletes.  
Another ever present issue in the context of sports is doping i.e. the use of prohibited 
performance enhancing drugs such as anabolic androgenic steroids (AAS) and growth factors. 
Since steroid doping is evaluated by measuring androgen metabolites in urine, it is important 
to understand the factors that affect endogenous androgen levels. In women, the interpretation 
of endogenous androgen levels is complex due to cyclic variations of androgens during the 
menstrual cycle, the influence of hormonal contraceptives and possibly the impact of genetic 
variations on androgen metabolism (20). There are known polymorphisms in genes coding for 
enzymes responsible for androgen transformation that affect the urinary steroid profile in men 
and possibly also serum and urinary androgen metabolite levels in women (21). Therefore, in 
study IV, we examined the impact of genetics and hormonal contraceptives on the urinary 
steroid profile in women, and in study V we compared the urinary steroid profile between 
female elite athletes and untrained controls and investigated the relationship between the 
urinary steroid profile and exercise.  
 
3 LITERATURE REVIEW 
 
3.1 ANDROGENS IN WOMEN  
 
3.1.1 Androgen production 
In women, de novo synthesis of androgens from cholesterol e.g. de novo steroidogenesis takes 
place in the ovary, adrenal gland and during pregnancy the placenta, resulting in biologically 
active androgens (T and dihydrotestosterone (DHT)) and precursor androgens 
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(dehydroepiandrosterone (DHEA), DHEA-sulphate (DHEA-S), androstenedione (A4), 
androstenediol (5-DIOL)). Androgens are released into the circulation and bind to the AR in 
the target tissue, resulting in a physiological response. Active androgens can directly bind to 
the AR, whereas precursor androgens require conversion to T or DHT before binding to the 
receptor (22).  
The ovarian and adrenal gland production of androgens are part of the hypothalamic-pituitary-
gonadal (HPG) - axis and the hypothalamic-pituitary- adrenal (HPA) - axis, respectively (22). 
The hypothalamus produces the gonadotropin-releasing hormone (GnRH) that binds to the 
secretory cells in the anterior pituitary gland, stimulating the production of follicle-stimulating 
hormone (FSH) and luteinizing hormone (LH), which in turn stimulate androgen production in 
the ovary (Figure 1 and 2) (23, 24).  
 
 
Figure 1: Androgen production of the ovary and adrenal gland. Androgens are synthesized in the theca cell by 
stimulation of LH and in the zona reticularis by stimulation of ACTH. In the ovary, androstenedione and 
testosterone can be released into the circulation or diffuse into the granulosa cell where FSH stimulates the 
transformation to estrone or estradiol via the enzyme aromatase. Prior to ovulation LH stimulates the granulosa 
cell to produce progesterone. ACTH=adrenocorticotropic hormone, DHEA=dehydroepiandrosterone, 
FSH=follicle-stimulating hormone, LH=luteinizing hormone. ©Emma Eklund.  
 
The adrenal production of DHEA-S and DHEA as well as cortisol secretion is stimulated by 
adrenocorticotropic hormone (ACTH) from the pituitary gland, in turn stimulated by 
corticotropic-releasing hormone (CRH) from the hypothalamus (22) (Figure 1 and 2). Both the 
HPG and HPA-axis are regulated by negative feedback mainly by estrogens, progesterone and 
cortisol respectively, as well as by other endogenous hormones and environmental factors (22) 






Figure 2: Illustration of the HPG-axis, HPA-axis and GH/IGF-I axis. The intracellular metabolism of precursor 
androgens by the mechanism of intracrinology and negative feedback mechanism of each hormonal axis are 
shown. The feedback of estrogen and progesterone on FSH and LH varies during the menstrual cycle. + indicates 
positive feedback, – indicates negative feedback. ACTH=adrenocorticotropic hormone, CRH=corticotrophin-
releasing hormone, DHEA-S=dehydroepiandrosterone-sulphate, DHEA=dehydroepiandrosterone, FSH=follicle-
stimulating hormone, GH=growth hormone, GHRH=growth hormone-releasing hormone, GnRH=gonadotropin-
releasing hormone, IGF-I=insulin-like growth factor-I, IGFBP-1=insulin-like growth factor binding protein-1, 
LH=luteinizing hormone. ©Emma Eklund.  
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In premenopausal women, T is directly produced by the ovary (25%) and by the adrenal gland 
(25%) whereas the remaining major part is derived from precursor androgens (23, 25, 26). The 
biotransformation of precursor androgens to active androgens within the tissue-specific cell, 
referred to as intracrinology or intracrine androgen metabolism, is especially important in 
women (Figure 2 and 3) (22, 26). DHT is primarily derived by T conversion via the enzyme 
5α-reductase, in the target tissue (25). These intracellular processes are possible in tissues that 
express steroid metabolizing enzymes such as in muscle, bone, skin and liver among others 
(22, 27).  
3.1.2 Sex hormone-binding globulin  
Both active androgens and precursor androgens derived from de novo steroidogenesis are 
transported in circulation to the target tissue, mainly by binding to sex hormone-binding 
globulin (SHBG) produced in the liver. Serum T binds strongly to SHBG (65-75%) and with 
less affinity to albumin (25-35%), whereas 1-3 % circulates as free T (20). Since only free 
active androgens are considered biologically active, SHBG levels in serum regulate androgen 
activity (20, 28). By calculating the free androgen index (FAI),((𝑇/𝑆𝐻𝐵𝐺)  × 100), free T 
can be estimated. Several factors affect SHBG levels, for example pregnancy and thyroid 
hormones increase SHBG, whereas high body weight, insulin and IGF-I decrease SHBG (29). 
In addition, hormonal contraceptives increase SHBG, where the elevation in SHBG levels is 
dependent on the estrogen dose and type and the type of progestin component (29, 30).  
3.1.3 The androgen receptor  
In the target tissue, the biological actions of androgens are mediated via the AR, a ligand-
controlled transcription factor part of the nuclear receptor superfamily located in the nucleus 
of target cells. The AR is present in several tissues important for body composition and physical 
performance such as bone, skeletal muscle and adipose tissue (31). Binding of T or DHT to the 
AR initiates conformational changes allowing the AR to activate transcription of androgen 
target genes (24, 32). This process is influenced by co-regulators affecting the ligand sensitivity 
and DNA binding capacity of the AR (32). In the final step, after binding to the AR, active 
androgens are metabolized into androgen metabolites in the target cell, released into circulation 
and then excreted mainly in urine, but also in feces and sweat (33, 34).  
3.1.4 Serum concentrations  
In premenopausal women, serum androgen concentrations, in descending order are DHEA-S, 
DHEA, A4, T and DHT (22, 25). Serum concentrations of precursor androgens, active 





Table 1. Endogenous androgens in women, serum concentrations determined by LC-MS/MS.  
Precursor Androgens  LC-MS/MC 
DHEA-S  6.0 (3.4-9.6) µmol/LA 
4.3 ± 0.02 µmol/L B 
DHEA  7.1 (4.2-11.8) nmol/LA 
3.4 ± 0.03 nmol/LB 
A4  5.9 (3.3-9.2) nmol/LA 
5-DIOL  1.5 ± 0.07 nmol/LD 
Active androgens 
  
T  0.3 (0.2-0.5) nmol/LA  
1.1 ± 0.09 nmol/LB 
0.0-1.7 nmol/LC  
DHT  0.4 ± 0.01 nmol/LB 
Androgen metabolites   
ADT -G  89 ± 0.7 nmol/LB 
2.1-170 nmol/LD 
3α-diol- 3G  0.5-9.2 nmol/LD 
3α-diol-17G  0.5-12 nmol/LD 
Etio-G   -  
A O’Reilly et al (2017). n=49 women, age 23-32 y. Median and interquartile range (35).  
B Zang et al (2017). pooled commercial serum. Mean and standard deviation for female serum (36). 
C Handelsman et al (2018). Summary of 9 research studies measuring serum T in healthy women, 
age <40 y. Lower-upper 95 % confidence interval (4).  
D Labrie et al (2006). 47 premenopausal women. Age 30-35 y. 377 postmenopausal women. Age 
55-65y min – max. Converted values nmol/L from Schiffer et al (2018) (27, 37).  
 
3α-diol- 3G=androstane-3α,17β-3 glucuronide, 3α-diol-17G=androstane-3α,17β-17 glucuronide, 
5-DIOL=androstenediol, A4=androstenedione, ADT-G=androsterone-glucuronide,  
DHEA-S=dehydroepiandrosterone-sulphate, DHEA=dehydroepiandrosterone, 
DHT=dihydrotestosterone, Etio-G=etiocholanolone-glucuronide,  








In women, the gonadal androgen productions starts during puberty, peaking at age 20-25 (4) 
whereas the adrenal androgen production is initiated during adrenarche (age 8 in girls) and 
reaches its peak at around 30-40 years of age (27). Several of the endogenous androgens decline 
with age and some vary across the normal menstrual cycle (23, 25, 31, 38). The physiological 
decline in DHEA-S, DHEA, T and A4 with age seems to be unrelated to natural menopause, 
whereas oophorectomy has been reported to reduce androgen levels by half (25, 38).  
3.1.5 Importance of DHEA for women 
DHEA and DHEA-S are the most abundant serum steroids in women. DHEA synthesis takes 
place in the adrenal gland (50%), in the ovaries (20%) and by conversion of DHEA-S (30%). 
Whereas, DHEA-S is predominantly produced in the adrenal glands (20, 23, 25, 26) (Figure 
3). In women a major portion of active androgens is produced by transformation of precursor 
androgens, mainly DHEA, by the mechanism of intracrinology (33). Circulating DHEA 
diffuses into the cell and is locally transformed into active androgens (T and DHT) able to bind 
to the AR. By contrast, in the classic endocrine route active androgens secreted by the gonads 
and adrenal gland are transported in the circulation to the target tissue where they bind directly 
to the AR without the need for prior transformation (26, 33, 34). In the final step, active 
androgens are metabolized into mainly glucuronide metabolites and then released into the 
circulation. During this process very small amounts of active androgens escape from the cell, 
hence not altering T and DHT serum levels significantly (27) (Figure 3). It has been suggested 
that in women, androgen metabolites reflect androgen activity and indirect tissue exposure to 
androgens in a more reliable way compared to serum T alone (37). It is now possible to 
accurately analyze serum levels of precursor androgens, active androgens and androgen 







Figure 3: Schematic picture showing the classic endocrine route of testosterone and the intrecellular metabolism 
of DHEA. AR=androgen receptor, DHEA=dehydroepiandrosterone, DHT=dihydrotestosterone, E2=estradiol. 
©Emma Eklund.  
 
3.2 ANDROGEN METABOLISM 
 
The androgen metabolism is complex, for clarity it can be divided into de novo steroidogenesis, 
intracrinology (also known as intracellular metabolism in peripheral androgen target tissue), 
see section 3.1.1, 3.1.5 (22, 26, 33), and finally inactivation of androgens by conjugation. The 
inactivation of androgens occurs in most tissues, although the liver is the major site. 
Conjugation of androgens makes the compound more water soluble, thereby facilitating 
excretion via mainly urine and bile (21, 22). In addition, feces and sweat have been suggested 
as alternative minor excretion routes although this remains to be studied in elite athletes (42-
44).    
3.2.1 Biotransformation of androgens  
Enzymes from the cytochrome P450 (CYP) family initiate the first step of steroid synthesis. 
CYP17A1 is responsible for the 17-hydroxylation of pregnenolone and progesterone and 
formation of precursor androgens, DHEA and A4 (21, 22, 34). It has also been suggested that 
CYP17A1 is involved in the formation of epitestosterone (EpiT), an epimer of T important in 
the context of doping testing (21, 45). In the next step various hydroxysteroid dehydrogenases 
enzymes are involved in the formation of T from DHEA, A4 and 5-DIOL (34). The active 
androgen T can then be transformed by either 5α-reductase to the active form 5αDHT or by 
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5β-reductase to 5βDHT, the former process occurs mainly in the liver and is important to 
maintain androgen homeostasis (22). T and A4 can also be biotransformed into estrogens via 




Figure 4: Illustration of the androgen metabolism. Important enzymes highlighted in purple and green, CYP17 
and UGTs. 5αAdiol=5α-androstane-3α,17β-diol glucuronide, 5βAdiol=5β-androstane-3α,17β-diol glucuronide 
5α-DHT=5α-dihydrotestosterone, 5β-DHT=5β-dihydrotestosterone, DHEA=dehydroepiandrosterone, DHEA-
S=dehydroepiandrosterone sulphate, UGT2B=UDP glucuronosyl transferase 2B. For clarity, 
androstenedione=A4, androstenediol=5-DIOL. ©Emma Eklund.  
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5α-DHT can then be metabolized to androsterone glucuronide (ADT-G), androstane-3α, 17β-
3 glucuronide (3α-diol-3G) and androstane-3α, 17β- 17 glucuronide (3α-diol-17G) via the 5α-
reduction pathway, whereas 5β-DHT is converted to etiocholanolone glucuronide (Etio-G) via 
the 5β-reduction pathway (34, 46, 47).  
The uridine-diphospho (UDP)-glucuronosyl transferases (UGTs) are the enzymes mainly 
responsible for the final formation of androgen metabolites, by glucuronidation, i.e. phase II 
metabolism (47, 48). The majority of androgens are metabolized in this manner, however small 
amounts are conjugated and excreted as sulphate metabolites after transformation by 
sulfotransferases (SULTs) (Figure 4) (21). These conjugated compounds are considered 
inactive, however while glucuronidation is irreversible, sulphate conjugation is reversible (22). 
After conjugation, androgen metabolites are excreted mainly in urine (21).  
There are known polymorphisms in the genes coding for CYP17A1, UGTs and SULTs that 
affect the urinary androgen metabolite levels in men (45, 49-51). In women less is known about 
how genetic polymorphisms affect serum and urinary androgen metabolites levels.  
3.2.1.1 CYPs 
As previously mentioned, CYP 17A1 is responsible for the hydroxylation of pregnenolone and 
progesterone (Figure 4) (21, 22, 34) and has been suggested to be involved in the formation of 
EpiT (21, 45). A promotor region polymorphism (T>C exchange) in the CYP17A1 gene has 
been described, with the CC variant hypothesized to upregulate gene expression, possibly 
affecting steroid hormone levels (52). In men, this polymorphism has been associated with 
significantly higher excretion of epitestosterone glucuronide (EpiT-G) in urine (45).   
3.2.1.2 UGT2B 
UGTs are divided into UGT1 and UGT2, in which the latter is subdivided into UGT2A and 
UGT2B. In the UGT2B subfamily the enzymes UGT2B17, UGT2B15 and UGT2B7 are 
responsible for the androgen glucuronidation due to their high capacity to conjugate androgens 
(Figure 4) (47, 48). T is mainly metabolized by UGT2B17 and to a lesser extent by UGT2B15 
and UGT2B7. UGT2B7 has been suggested as the main enzyme responsible for the 
glucuronidation of EpiT in vitro (21, 45). In men with a deletion polymorphism in the 
UGT2B17 gene (del/del), urinary testosterone glucuronide (T-G) levels were negligible and 
significantly lower compared to individuals with one (ins/del) or two copies (ins/ins) of 
UGT2B17 (21, 45, 49). For UGT2B7 and UGT2B15, polymorphisms have been identified that 
lead to a shift in amino acids. For UGT2B7 a missense polymorphism results in the replacement 
of histidine with tyrosine at position 268 (45, 53) and a polymorphism in the UGT2B15 gene 
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leads to a change of aspartate to tyrosine at position 85 (21, 45). In men, individuals with a 
UGT2B7 YY genotype demonstrated higher serum androgens compared to the HH and HY 
genotype, although urine levels of DHT, T and the testosterone/epitestosterone (T/E) ratio were 
not associated with the UGT2B7 polymorphism (54).  
3.2.2 Doping detection 
Some athletes use doping agents such as AAS, growth hormone (GH) and/or IGF-I to increase 
muscle growth and enhance performance (5, 55, 56). Currently, androgen abuse is evaluated 
using traditional testing and/or the athlete biological passport (ABP). Traditional testing refers 
to the analysis of androgen metabolites in urine in a single sample and calculation of specific 
ratios of urinary steroid, comparing these to population-based reference ranges, whereas the 
ABP implements a longitudinal approach.  
To detect androgen abuse, the urinary steroid profile is currently determined using gas 
chromatography-tandem mass spectrometry analysis (GC-MS/MS), analyzing the urinary 
biomarkers T-G, EpiT-G, ADT-G, Etio-G, 5α-androstane-3α,17β-diol glucuronide (5αAdiol-
G), 5β-androstane-3α,17β-diol glucuronide (5βAdiol-G). Since GC-MS/MS cannot distinguish 
between exogenous and endogenous androgens several ratios have been determined that 
indirectly measure androgen abuse, such as the T/E ratio. In men, exogenous T abuse increases 
urinary T-G and decreases its epimer EpiT-G resulting in an increased T/E ratio (57-59). In 
women, the effects of exogenous T on EpiT-G levels are more variable (60, 61). Traditionally, 
in elite athletes a T/E ratio above 4 is indicative of T abuse (21, 62). Additional ratios are also 
determined and atypical findings confirmed using the isotope ratio mass spectrometry (IRMS), 
able to distinguish between endogenous and exogenous androgens (58, 59).  
The ABP consists of the hematological module introduced in 2009, followed by the steroid 
module initiated in 2014. The steroid module evaluates urinary androgens, however serum 
androgen levels may be added in the future (63). Furthermore, the endocrine module is 
currently under development focusing on the detection of GH, IGF-I and insulin doping (57, 
58). The ABP monitors selected biomarkers using a longitudinal approach. Individual reference 
limits for these biomarkers can be calculated using specific algorithms and a Bayesian 
statistical method is used to progressively shift the comparison of the athlete’s androgen levels 
from population-based reference ranges to the athlete’s own reference ranges (59). Any 
significant change in these individual reference ranges raises suspicions of doping. By 
monitoring the individual athletes over time, subtle changes in biomarkers can be detected. In 
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addition, confounding factors such as genetic polymorphisms can be added to the statistical 
model and accounted for (62).  
Both endogenous and exogenous factors can affect the interpretation of the urinary steroid 
profile. Genetic polymorphisms are the major confounders (21, 62), which could lead to both 
false negative and false atypical findings (21, 49, 64). The implementation of the ABP increases 
the chance to detect doping in men (65, 66). However, in women T administration is not 
necessarily detected either by traditional testing or the ABP (61, 67). Suggested important 
confounding factors with regard to doping detection in women are hormonal fluctuations 
during the menstrual cycle and the use of hormonal contraceptives (62, 68-70). Prior to study 
IV, part of this thesis, only one small report (n= 4 women) investigating the effects of hormonal 
contraceptives on the urinary steroid profile had been published. The authors found that 
hormonal contraceptives affect the T/E ratio, suggesting suppression of EpiT-G as a possible 
mechanism responsible for this change (68, 71). 
 
3.3 PRENATAL ANDROGEN EXPOSURE 
 
During pregnancy, the fetal/placental endocrine system produces and metabolizes steroid 
hormones in complex interaction with the maternal hormonal system (72). Androgens in 
prenatal blood/fetal blood can be determined directly by cordocentesis during the second or 
third trimester. However, due to the increased risk to the fetus, this procedure is rarely 
implemented and then only in high-risk pregnancies. Fetal androgens can also be determined 
at birth from umbilical cord blood, then reflecting only late gestation. Indirect approaches to 
measure fetal androgens include amniocentesis (restricted to high-risk pregnancies) during the 
second or third trimester or maternal blood sampling to evaluate hormonal levels (72, 73). Due 
to the invasive nature of these procedures and the risk to the pregnancy/fetus other indirect 
measurements of the prenatal androgens have been proposed such as the 2D:4D ratio i.e. the 










Figure 5: Measurement and calculation of the second to fourth digit (2D:4D) ratio. Photo: Emma Eklund. 
Originally published and reprinted from Frontiers in Endocrinology, vol 11, article 292, p 1-8; Copyright 2020. 
Open access. CC-BY license (75).  
 
3.3.1 The 2D:4D ratio  
Prenatal testosterone and estrogen levels have been suggested to influence the formation of the 
2D:4D ratio (74, 76, 77). Previous studies have reported that the 2D:4D ratio is set during the 
first trimester of fetal development, as early as 9 weeks of gestation, with high levels of 
androgens during fetal life resulting in a low 2D:4D ratio (74, 78). It is considered a sexually 
dimorphic trait (74, 79) and does not change substantially with age in adults (74, 80).  
In light of this, researchers have suggested the 2D:4D ratio may be an indirect measurement of 
prenatal androgen exposure (74). However, it should be noted that this concept has recently 
been debated (81-84). In table 2, studies examining the relationship between 2D:4D ratio and 






Table 2: Studies investigating prenatal androgen exposure and 2D:4D ratio.  
Author (citation) Method Results 
Lutchmaya 2004 (76) FT and FE in amniotic fluid, 
second trimester. 2D:4D r at 
follow-up, child age 2 y. n=33 
children (15 f, 18 m) 
FT/FE (high FT in relation to FE) 
significant negative association with 
2D:4D r.  
Ventura 2013 (85) FT in amniotic fluid and T 
maternal blood sample. 2D:4D r 
in healthy born infants and 
mothers (n=106) 
FT higher in males than in females. 
No correlation between FT and 
maternal T. FT in females 
negatively correlated with 2D:4D r.  
Hickey 2010 (73) Androgens in cord blood, 
androgens in maternal blood 
second and third trimester. 
2D:4D r in offspring, adolescent 
girls (n=244) at measurement.  
No significant correlations were 
found.  
Hollier 2015 (86) T, A4, DHEA, and estrogens in 
cord blood*. 2D:4D r in f and m 
offspring at 19-22 y (n=341).  
Males lower 2D:4D r compared to 
females. No significant correlations 
between 2D:4D r and fetal 
androgens and estrogens at late 
gestation.  
Whitehouse 2015 (87) T in cord blood*. 2D:4D r in f 
and m offspring at 21-24 y 
(n=183).  
Males lower 2D:4D r compared to 
females. No correlation significant 
correlations found between cord T 
and 2D:4D r.  
Mitsui (2016) (88) Adrenal androgens in cord 
blood*. 2D:4D r in f and m 
offspring at school-age (n=190) 
Males lower 2D:4D r compared to 
females. DHEA negatively 
correlated with 2D:4D r in males.  
Malas (2006), (78) n= 161 aborted fetuses (78 f, 83 
m, age 10-40 weeks). 2D:4D r 
established.  
Significant difference in 2D:4D r 
between sexes. No significant 
change in 2D:4D r over gestational 
ages.  
Zheng (2011) (77) 58 CD-1 mice (30 m, 28 f). 
Hind limb 2D:4D r measured. 
ER and AR estimate in 2D and 
4D.   
Sexually dimorphic trait in mice. 
Higher AR and ER in 4D than 2D. 
Inactivation/Activation of receptors 
influence the 2D:4D r.  
2D:4D r=second to fourth digit ratio right hand, A4=androstenedione, AR=androgen receptor, 
ER=estrogen receptor, DHEA=dehydroepiandrosterone, f=female, FE=fetal estrogen, FT=fetal 
testosterone, m=male, T=testosterone, y=years old. *analyzed by liquid chromatography- tandem 






Previous investigations have reported that females with congenital adrenal hyperplasia, a 
condition with increased androgen exposure in utero, have a lower 2D:4D ratio compared to 
healthy controls (79), a recent meta-analysis revealed similar, but less strong findings (89). 
Additionally, women with complete androgen insensitivity syndrome, having no response to 
androgens due to a non-functioning AR, have higher 2D:4D ratios than control women (90, 
91). The 2D:4D ratio has also been related to athletic ability and physical fitness (92, 93).  
3.3.2 The 2D:4D ratio in sports  
The 2D:4D ratio is considered lower in athletes compared to non-athletes. However, previous 
studies have focused on male athletes participating in power/explosive sports (94-96), whereas 
data on 2D:4D ratio in female top elite athletes is limited. One study examined the 2D:4D ratio 
in female varsity athletes and controls and found lower ratios in the athlete population (97). In 
agreement, a lower 2D:4D ratio has been found among female tennis, handball and fencing 
athletes when compared to nonathletic controls (98-100). These studies have included few 
participants and no female Olympic level athletes have been represented. Others have found an 
association between a lower 2D:4D ratio and sporting level or performance in specific sport 
such as alpine skiing, fencing and rowing (101-103).  
The cause of the correlation between 2D:4D ratio and physical performance and the reason for 
the lower 2D:4D ratio in athletes compared to non-athletes are not known. Initially researchers 
debated a possible link to adult serum T levels, however, two meta-analyses from 2007 and 
2019 concluded that the digit ratio is not related to adult serum T levels (104, 105). Others have 
proposed a connection between the 2D:4D ratio and genetic variations in the AR, although 
recent investigations have indicated no such association (104, 106). Furthermore, genetic 
variants in selected genes coding for certain androgen metabolizing enzymes (aromatase, 5a-
reductase) and SHBG have been examined in relation to the 2D:4D ratio without significant 
results (104). However, no previous studies have examined potential associations between the 
2D:4D ratio and serum and urinary androgen metabolites, more representative of phase II 
androgen metabolism, in women Olympic athletes. 
 
3.4 GROWTH HORMONE/INSULIN-LIKE GROWTH FACTOR-I  
 
The peptide hormone IGF-I is an anabolic hormone, stimulating protein synthesis and cell 
proliferation with positive effects on adult bone metabolism and skeletal muscle (107, 108). 
GH secreted in a pulsatile manner from the pituitary gland stimulates the production of IGF-I 
 
 27 
from the liver and non-hepatic tissues. The stimulatory effect of GH is dependent on the 
presence of insulin and amino acids. During malnutrition GH cannot stimulate IGF secretion. 
The secretion of GH is regulated primarily by growth hormone-releasing hormone (GHRH) 
(stimulating), ghrelin (stimulating) and somatostatin (inhibiting) from the hypothalamus. 
Furthermore, free IGF-I regulates GH secretion by negative feedback (Figure 2) (108). The 
majority (98-99%) of circulating IGF-I is bound to IGF binding proteins (IGFBPs) (109), thus 
in serum we determine total IGF levels not free IGF-1. IGF-I binds to the transmembrane 
tyrosine kinase IGF-I receptor part of the tyrosine kinase receptor family. It also binds with 
lower affinity to the insulin receptor and the hybrid insulin/IGF receptor (109).  
The anabolic effects of GH are to a large extent mediated by circulating IGF-I (55). In addition, 
locally produced IGF-I can act via para- and autocrine mechanisms (108-110). In contrast to 
GH, total IGF-I levels are more stable and show little day-to-day intraindividual variability 
(108). Furthermore, total IGF-I levels have been shown to be comparable between men and 
women (111). However, it is well known that total IGF-I levels decrease with age (112, 113). 
Steroid hormones (androgens and estrogens) are suggested to regulate the actions of GH and 
IGF-I (114). Androgens stimulate GH secretion and circulating IGF-I, after aromatization to 
estrogen (115). In women, the use of estrogen therapies, may alter the GH/IGF axis, with oral 
estrogens inhibiting hepatic IGF-I production by first-pass estrogen effects while non-oral 
administration has no effect or increases IGF-I (116). Furthermore, small to moderate changes 
in IGF-I levels have been reported during the menstrual cycle (117-120).  
3.4.1 IGFBPs 
The IGFBPs have serum and tissue specific expression and act as transport proteins, regulate 
IGF-I bioavailability and prolong the half-life of IGF-I (107, 109, 121). Currently, there are six 
known IGFBPs (109). Circulating IGF-I is primarily bound (approximately 75 %) in a ternary 
complex with IGFBP-3 or 5 and Acid-label unit, 20-25% is bound in a binary complex with 
other IGFBPs e.g. IGFBP-1 or IGFBP-2, whereas only approximately 1-2 % circulate in free 
form (5, 121). Only IGF-I in its free form or as a binary complex can diffuse from circulation 
to the interstitial fluid then being able to bind to the IGF-receptor (121). It is now recognized 
that IGFBPs also have IGF-I independent effects at the cellular level by binding to an integrin 
receptor (107, 109, 121, 122).  
IGFBP-1 production takes place in the liver and is mainly regulated by insulin at transcriptional 
level and to a lesser extent by catecholamines, glucagon and cortisol. Insulin inhibits, whereas 
catecholamines, glucagon and cortisol stimulate the hepatic production of IGFBP-1 (109, 122). 
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Therefore, in the non-fed state when insulin levels are low, inhibition of IGFBP-1 decreases, 
resulting in higher IGFBP-1 levels, the effect being further augmented by glucagon and 
cortisol. In the well-fed state the opposite occurs resulting in lower IGFBP-1 levels and 
increased IGF-I bioavailability. Due to its strong relation to insulin, circulating IGFBP-1 is 
positively associated with insulin sensitivity and has therefore been proposed as a marker of 
the latter (109). Furthermore, hypoxia stimulates IGFBP-1 synthesis via hypoxia inducible 
factor 1-alpha (HIF-1-a) at transcriptional level (123, 124). IGFBP-1 stimulates vascular nitric 
oxide (NO) synthesis and thus vasodilatation and blood flow (122). High-intensity exercise is 
associated with hypoxic reactions and increased HIF-1a (125) and increased IGFBP-1 (110).  
 
3.5 THE FEMALE ATHLETE  
 
In women, endogenous hormones fluctuate during the menstrual cycle and can be affected by 
hormonal contraceptive use. Furthermore, endocrine disturbances are common in female elite 
athletes often resulting in menstrual dysfunction. These hormonal disturbances can be a result 
of intense training, energy deficiency or essential hyperandrogenism (8, 126). The latter is 
suggested to have anabolic effects on body composition and possibly performance enhancing 
effects of relevance for the female athlete.  
3.5.1 The menstrual cycle 
The normal menstrual cycle is approximately 22-34 days and is divided into the follicular-, 
ovulation- and luteal phase related to ovarian changes, or the secretory- and proliferative phase 
of the endometrium. During the normal menstrual cycle, gonadotropins and steroid hormones 
vary. The fluctuations in gonadotropins, estradiol (E2) and progesterone are well established 
(127-129). DHT levels are low in women and do not fluctuate during the menstrual cycle, 
whereas T levels increase simultaneously in response to the LH peak during ovulation and last 
for approximately 2-3 days (128-130). This mid-cycle increase in T is however small and is 
within the physiological range of premenopausal women (4). Possible cyclic variations in 
adrenal androgens are less studied, however several investigations have demonstrated no 
significant difference in 5-DIOL, DHEA and DHEAS levels across the menstrual cycle (129-
131) (Figure 6). As for IGF-I, variations during the menstrual cycle have been described to be 





Figure 6: Illustration of the menstrual cycle showing hormone fluctuations during the different cycle phases. 
DHEA=dehydroepiandrosterone, DHEA-S=dehydroepiandrosterone-sulphate, FSH=follicle-stimulating 
hormone, LH=luteinizing hormone. ©Emma Eklund.  
3.5.1.1 Menstrual dysfunction  
Endocrine disturbances can result in menstrual dysfunction being categorized as amenorrhea 
(absence of menstruation during at least three months) or oligomenorrhea (5-9 periods during 
the past year occurring at intervals greater than six weeks). In the general population menstrual 
dysfunction ranges between 2-4 % (132, 133). Whereas, in female athletes it is frequent, 
ranging between 6-78%, the prevalence being higher among female athletes participating in 
endurance or esthetic sports (134-136).  
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Athletic amenorrhea, a form of functional hypothalamic amenorrhea is probably the most 
common cause of menstrual dysfunction among female athletes. Intense physical training and/ 
or low energy intake cause insufficient energy availability, leading to inhibition of the HPG 
axis. The disruption of the pulsatile release of GnRH results in reduced FSH and LH secretion 
and in turn lower estrogen, testosterone and progesterone, causing anovulation and amenorrhea 
(8, 137). In addition, insulin and IGF-I levels decrease whereas cortisol and IGFBP-1 are high. 
Taken together these hormonal changes can result in bone loss and increased risk of injury (8, 
126).  
An alternative explanation for menstrual dysfunction in female athletes is polycystic ovary 
syndrome (PCOS) (136), clinically characterized by polycystic ovaries and disturbed ovulation 
resulting in menstrual dysfunction, hirsutism and acne (8, 137). These symptoms are a results 
of increased androgen production in the ovaries, being attenuated by the disturbed negative 
feedback of GnRH resulting in higher LH. Furthermore, insulin resistance is common among 
PCOS women and insulin directly stimulates androgen production in the ovary and inhibits the 
hepatic SHBG production resulting in higher levels of free androgens able to bind to the AR 
(8). In contrast to functional hypothalamic amenorrhea, PCOS is associated with a more 
anabolic body composition and positive effects on physical performance (136, 138).  
3.5.2 Hormonal contraceptives  
Hormonal contraceptives include oral pills, patches, vaginal ring, subdermal implants, 
injections and intrauterine devices containing components of estrogen and/or progestin. The 
most common estrogen component in combined hormonal contraceptives is synthetic 
ethinylestradiol. Furthermore, the progestin component varies, as well as the dose of each 
component. The contraceptive effect is mainly induced by preventing ovulation by feedback  
on the HPG axis, alternatively altering the cervical mucus or by effects on the endometrium 
(139). In a previous study including Swedish female Olympic athletes approximately 40-50 %, 
used hormonal contraceptives (136).   
3.5.2.1 Androgens  
The anovulatory action of hormonal contraceptives is established via inhibition of the HPG 
axis, resulting in suppression of GnRH, followed by a decrease in gonadotrophins, ovarian 
steroid hormones and probably adrenal androgens. Combined oral contraceptives (COCs) 
induce a decrease in serum total T and increase in SHBG resulting in lower levels of free T 
(30, 139). An average decrease of 31 % in total T levels has been reported whereas the increase 
in SHBG is dependent on the estrogen and progestin component of the COC (30). The effects 
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on adrenal androgen levels are less established although recent findings show a decrease in 
these hormones (30, 140, 141). Women using hormonal contraceptives have significantly lower 
serum androgens and gonadotrophins and significantly higher levels of SHBG (142, 143), 
however changes in urinary androgen glucuronide metabolites are not fully elucidated. 
3.5.2.2 GH/IGF-I  
The effects of hormonal contraceptives on the GH/IGF-I system are dependent on the type of 
estrogen, the duration of treatment, dose and especially the route of administration. Although 
there is limited knowledge of the effect of hormonal contraceptives on IGF-I levels in 
premenopausal women, there is evidence that oral estrogens decrease circulatory IGF-I levels 
through hepatic first- pass effects. It has been suggested that estrogen metabolism in the liver 
suppresses hepatic IGF-I production and alters hepatic IGFBP production resulting in 
decreased IGF-I bioavailability. In contrast, non-orally administered estrogens result in less or 
no change in IGF-I levels. Further complicating the situation, combined treatment with a 
progestin can modulate the GH/IGF-I response depending on the androgenic profile of the 
progestin (116). Two previous investigations including female athletes found no significant 
difference in IGF-I levels depending on hormonal contraceptive use (143, 144). Whereas 
IGFBP-1 levels are higher in hormonal contraceptive users (136, 143).   
3.5.3 Hyperandrogenism  
Essential hyperandrogenism may be mild or severe depending on the cause. Hyperandrogenism 
is overrepresented among female athletes compared to women in general, and it is suggested 
that the higher endogenous androgen levels may results in performance enhancing effects (4, 
136, 142). PCOS is the most common cause of mild hyperandrogenism, affecting 
approximately 6-10% of women. Women with PCOS often exhibit androgen levels in the upper 
normal female range and far from the male range (4). Previous studies have shown that women 
with PCOS have greater muscle strength compared to non-PCOS women which has been 
suggested to be related to the elevated androgen levels (145). Furthermore, female athletes with 
PCOS demonstrate higher aerobic performance values than non-PCOS athletes (138) and high 
BMD and lean mass (136). 
Other rare conditions known as 46 XY DSD, result in significantly elevated active androgen 
levels, comparable to those of men (11). DSDs are congenital conditions leading to atypical 
chromosomal, gonadal or anatomical sex. There are several forms of 46 XY DSD, all exhibiting 
somewhat different phenotypes and various degree of androgen sensitivity. However, it is 
important to acknowledge that only 46 XY DSD individuals with a functioning AR can benefit 
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from the anabolic effects of T and DHT (146). Among female athletes, there is an 
overrepresentation of 46 XY DSD individuals, being 140 times more common compared to the 
general population (142). A recent study found that female athletes with 46 XY DSD had a 
median T level of 18 nmol/L, being significantly elevated compared to female athletes in 
general (median T 0.69 nmol/L) (142). Individual case studies have reported that testosterone 
lowering treatment in these individuals also reduced physical performance by approximately 
5.7 % (147). Other conditions that may result in increased androgen levels are for instance 
androgen secreting tumors and AAS doping. Furthermore, both male and female transgender 
athletes may have high androgen levels depending on treatment (4).  
 
3.6 ANABOLIC EFFECTS OF ANDROGENS  
 
Androgens have anabolic effects on bone and muscle tissue, stimulate erythropoiesis and the 
immune system, and may affect behavior (4, 148, 149). It is well known that endogenous 
androgens and estrogens play an important role in bone health. T can bind to the AR expressed 
in both osteoblasts and osteocytes or act indirectly by aromatization to estrogen, both pathways 
promoting bone formation (149-151). In muscle, T increases the number of myonuclei and 
satellite cells and muscle fiber size and number. Furthermore, T increases erythropoietin levels 
resulting in higher hemoglobin concentrations (4). Taken together these effects are likely to be 
beneficial for athletic performance by a likely increase in muscle strength, bone formation and 
maximal oxygen uptake/ aerobic capacity. 
In men, there is a well-established relationship between both exogenous and endogenous 
androgens and a more anabolic body composition and increased physical performance (4, 6, 
16, 152-154). However, in women, especially female athletes, less is known about exogenous 
and endogenous androgen effects on body composition and physical performance.  
3.6.1 Exogenous androgens, body composition and physical performance 
In young healthy males, T administration follows a dose-response relationship with anabolic 
effects on bone, muscle mass and increased muscle strength (152, 153). On the other hand, in 
women the connection is less well established, probably due to ethical concerns such as 
potential adverse effects of T administration. Additionally, in female athletes there is the 
obvious problem of exogenous androgens being classified as doping agents and prohibited in 
sports (8).  
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In premenopausal women with hypopituitarism, resulting in hypogonadism and/ or adrenal 
insufficiency, androgen supplementation increased both bone mineral density (BMD) and lean 
mass compared to placebo (155). Whereas, in postmenopausal women, higher doses of T 
supplementation (resulting in mean serum T concentration 7.3 nmol/L) increased muscle mass 
and strength compared to both placebo and lower doses of T (156). Furthermore, in transgender 
men (biological female to male transgender) receiving T treatment resulting in circulating T 
levels within the normal male range, muscle mass and muscle strength significantly increase 
(4, 157).  
There are no well-controlled scientific investigations studying androgen supplementation in 
female elite athletes. However, there is indirect evidence supporting the anabolic effects of 
androgens, such as the continuous use of AAS among athletes with reports of increased strength 
and training ability (7). Data concerning women and AAS is limited, except for experiments 
performed in the former DDR. Documentation revealed that the athletes were subjected to AAS 
from an early age and that the performance enhancing effects were especially prominent in 
female athletes (15). In a recently published randomized controlled trial, including healthy, 
premenopausal, physically active women the effects of T supplementation on body 
composition and physical performance were evaluated. In the group given exogenous T, serum 
T levels increased from mean 0.9 to 4.3 nmol/L, and lean mass and aerobic performance 
increased significantly compared to the placebo group (18) supporting an anabolic effect of 
exogenous T in women.   
3.6.2 Endogenous androgens, body composition and physical performance  
In postmenopausal women, high endogenous free T has been associated with a lower 
prevalence of osteoporotic fractures and positively related to lean mass (158, 159). Also, in 
non-athletic PCOS women, free T correlated positively to lean mass (145). When starting this 
PhD project in 2015, there was a lack of scientific studies investigating anabolic effects of 
endogenous androgens within the normal range in female elite athletes, see table 3. Most 
previous studies included either a small study group, no control group, analyzed only certain 
androgens, analyzed T by radioimmunoassay (RIA) and not by mass spectrometry, or did not 






Table 3. Studies investigating endogenous androgens, body composition and physical performance 
in female elite athletes.  
Author (citation) Method Results 
Rickenlund 2003 (138) Female athletes with menstrual 
dysfunction (n=25), regularly 
menstruating female athletes 
(n=14), sedentary regularly 
menstruating controls (n=12). 
Hormonal analyses by RIA, 
body composition, physical 
performance.  
Female athletes with 
hyperandrogenism > BMD, beep 
test, VO2 max, then female athletes 
with normal androgen levels. T 
positively correlated to lean mass 
and VO2 max. 
Cardinal 2006 (16) Female elite athletes (n=22). 
Serum T analyzed by RIA. 
Physical performance.  
Positive correlation between 
endogenous serum T and CMJ 
(explosive performance).  
Crewther 2010 (17) Female Olympic weightlifters 
(n=4). Salivary T analyzed by 
RIA. Physical performance.  
No correlation between pre-work 
out T and snatch, clean and jerk, 
and front squat 1RM.  
Hagmar 2009 (136) Female Olympic athletes 
(n=90). Body composition. 
Menstrual function. 
Gynecological ultrasound. 
Hormonal analyses by RIA.   
Most common cause for menstrual 
dysfunction = PCOS. PCOS athletes 
had higher androgen levels. Power 
athletes had significantly higher 
BMD and lean mass compared to 
endurance and technical athletes. 
No data published on correlations 
between androgens and lean mass.  
   
Bermon 2017 (19) 1332 observations of elite 
female athletes. T and 
androstenedione by LC-MS. 
Best race performance for each 
athlete recorded.  
Female athletes with the higher T 
tertile had significantly higher 
performance (1.8-4.5%) in 400 m, 
800 m running, hammer throw and 
compared to female athlete with the 
lowest T tertile.  
1RM=one repetition maximum, BMD=bone mineral density, CMJ=countermovement jump, LC-
MS=liquid chromatography mass spectrometry, PCOS=polycystic ovary syndrome, 
RIA=radioimmunoassay, T=testosterone, VO2max=maximal oxygen uptake.   
 
Others have compared endogenous T levels between female athletes and controls (160, 161). 
Tegelman et al (160) found no difference in T levels between female endurance athletes (n= 
10) and untrained controls (n=13). In agreement, comparable T levels have been demonstrated  
between female kayakers (n=21), judokas (n=22) and non-athletic students (n=19) (161). A 
more recent study, including only nine elite, nine non-elite female athletes and no sedentary 
controls, found significantly higher salivary T in the elite athletes compared to non-elite 
athletes (162). Importantly, the immunoassay methods used for determining androgen levels in 
these studies were not as sensitive and specific as the current gold standard method LC-MS/MS 
(163) and therefore precursor androgens or androgen metabolites could not be measured. 
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3.7 ANABOLIC EFFECTS OF THE GH/IGF-I SYSTEM  
 
The GH/IGF-I system has anabolic properties on muscle, bone and on collagen synthesis 
(tendons, extra cellular matrix) (5, 107, 108, 121, 164, 165). GH per se has lipolytic effects and 
stimulates gluconeogenesis supplying substrates for growth. These effects may result in 
improved athletic performance and/or increased training capacity. In GH deficient adults, the 
anabolic effects of GH replacement therapy are well established, including increased physical 
performance (164, 166, 167). However, it is questioned if GH/IGF-I supplementation exerts 
similar performance enhancing effects in healthy subjects (115, 166, 168-170). Even so, 
professional and recreational athletes use these substances as doping agents (5, 166, 171), 
despite both GH and IGF-I use being banned from sports by the World Anti-Doping Agency 
(WADA) (115). For female athletes, the role of endogenous IGF-I for body composition and 
physical performance is unclear.   
3.7.1 Exogenous GH and IGF-I, body composition and physical performance  
In adults with GH deficiency, GH supplementation results in increased IGF-I levels and lean 
mass and reduced fat mass as well as increased maximal oxygen uptake and power output (164, 
166, 167). Although exogenous GH given to healthy adults has similar effects on body 
composition, no increase in aerobic capacity or muscle strength has been demonstrated in this 
population (164, 168-170).  
Two previous randomized controlled trials have examined the effect of GH and IGF therapy in 
recreational athletes (172, 173). Meinhardt et al (172) found an increase in lean body mass,  a 
decrease in fat mass and a 3.9 % increase in sprint performance after 8 weeks of GH therapy 
compared to placebo. These effects were even greater in the GH + T supplement group (men 
only). However, the authors concluded that GH primarily increased extracellular water, while 
testosterone had a greater influence on body cell mass (the functional compartment of lean 
body mass) (172). Others found that administration of an IGF-I compound to recreational 
athletes resulted in no significant changes in body fat or lean body mass, but a significant 





3.7.2 Endogenous IGF-I, body composition and physical performance 
To the best of our knowledge no previous studies have examined the relationship between 
endogenous IGF-I and physical performance in female athletes. However, in untrained women 
IGFBP-2 has been positively related to peak oxygen uptake (174). In contrast, Eliakim et al 
(175) found no significant association between IGF-I and aerobic performance.  
Three previous investigations have examined IGF-I in relation to body composition in female 
athletes. In a population of 23 female athletes, Snow et al (176) found significant positive 
correlations between IGF-I, BMD and lean mass (176). Additionally, Ehrnborg et al (177) 
measured IGF-I in response to a maximum exercise test and found that IGF-I was positively 
correlated with weight in 33 female athletes. Lean mass, BMD and fat percent were not 
measured in this study and potential correlations between exercise test and baseline hormonal 
data was not reported. In a large study by Healy et al (14), including 92 female athletes, no 
significant association was found between IGF-I levels and body fat.  
Others have compared endogenous IGF-I levels between female athletes and controls 
demonstrating varying results (176, 178, 179). Limitations of these studies are the low number 
of participants, and the fact that although IGF-I is known to decrease with age (112, 113), age-
adjustment or age-adjusted IGF-I was not reported. The exception is a large study by Healy et 
al (180), demonstrating higher post-competition endogenous IGF-I levels in elite athletes 
compared to resting IGF-I levels in non-athletic controls. However, comparison of resting IGF-
I levels between athletes and controls was not performed. Furthermore, endogenous IGF-I 




4 RESEARCH AIMS 
 
4.1 GENERAL AIMS  
 
The overall purpose of this thesis was to improve our knowledge of the relationship between 
endogenous anabolic hormones, body composition, physical performance and the 2D:4D ratio 
in female elite level athletes. Furthermore, the aim was to evaluate the impact of genetics and 
hormonal contraceptive use on the urinary steroid profile in athletes and examine the 
relationship between serum and urinary androgens in women.  
 
4.2 STUDY SPECIFIC AIMS   
 
Study I. To examine the endogenous serum androgen profile in female Olympic athletes 
compared to controls and between sport categories and in relation to body composition and 
physical performance.  
Study II. To investigate the 2D:4D ratio in female Olympic athletes compared to controls and 
in relation to endogenous serum and urinary androgens and physical performance. 
Study III. To examine endogenous IGF-I, age-adjusted IGF and IGFBP-1 in female Olympic 
athletes compared to controls, between sport categories and in relation to body composition 
and physical performance.  
Study IV. To evaluate the impact of hormonal contraceptive use and genetic variations on the 
urinary androgen steroid profile in female elite athletes.  
Study V. To investigate the urinary steroid profile in female Olympic athletes compared to 




5 MATERIALS AND METHODS 
 
In the following section the study population is presented in detail, whereas methods are 
presented focusing on strengths and limitations. A detailed description of each method is 
presented in previously published papers (75, 181, 182) and manuscripts as part of this thesis 
and/or in papers cited on the methods applied (39, 40, 112, 183-188).  
 
5.1 STUDY POPULATION AND OVERVIEW OF STUDIES   
 
This thesis includes five studies where studies I, II, III and V are based on the same study cohort 
consisting of Swedish Female Olympic athletes, n=106 (Swedish Olympic Committee (SOC) 
study cohort) and untrained controls, n=117. In study IV, 57 of the female athletes participating 
were part of the SOC study cohort. Written informed consent was given by all participants. In 
addition, blood and urine samples from 22 female elite athletes that had given consent to 
participate in research in their anonymous doping control forms were included (Table 4). The 
studies were approved by the Regional Ethics Committee (Dnr 01-146 and Dnr 2011/1426-
32).  
Participants in the SOC study cohort were investigated at the Women’s Health Research Unit, 
Karolinska University Hospital or in connection with training camps. Recruitment started in 
2011 and continued until 2015 when a representative number of athletes had been included. 
Female athletes (>18 y), members of a Swedish Olympic team or part of the high-performance 
program of the SOC were eligible for inclusion. During the recruitment period two Olympic 
games were held, the summer games in London 2012 and the winter games in Sochi 2014. In 
total, 106 Swedish female athletes participated in these Olympic games (London n=81, Sochi 
n=45). For these Olympic team members, 15 did not respond and 5 declined citing a busy 
schedule and training and competing and living in distant locations as primary reasons. In total, 
86 women athletes that participated in the 2012 and 2014 Olympic games were included in the 
SOC study cohort. In addition, 20 female athletes who were part of the high-performance 
program of the SOC and/or part of the 2016 Olympic games were included in the study. In the 





Athletes were divided into sport categories, Power (sport disciplines involving short bursts of 
intense exertion and high mechanical load), Endurance (sport disciplines involving prolonged 
periods of submaximal exertion and low mechanical load), Technical (disciplines with a low 
demand on physical exertion and low mechanical load and focus on technical skills) depending 
on type of sports (Figure 7) as previously described (182).  
 
 
Figure 7: Illustration showing the type of sports in each sport category, power, endurance and technical.  
 
Furthermore, 128 controls were recruited via advertisement at the Karolinska Institutet and 
online, via a Swedish scientific study recruitment webpage (www.studentkaninen.se). 
Inclusion criteria were a maximum 2 h training/ week, no prior participation in elite level sports, 
and age 18-45 years. The controls were initially approached via e-mail, in the order of which 
they had signed up interest and given written information about the study. Eleven controls were 
excluded (n=1 prior participation in elite level sports, n=8 training load higher than inclusion 
criteria, n=2 too high BMI ≥30). In total 117 women controls were included in the study.  In 
table 4, an overview of the studies part of this thesis is presented, including study subjects, 






Table 4. Overview of study subjects, study design, methods and analyses made.  
 
Study  Study subjects Study design  Methods  Analyses 





SOC physical profile 
 
Serum androgens 
FSH, LH, SHBG 
Body composition  
SJ, CMJ 
II 104 athletes*  
117 controls  




SOC physical profile  
 




CMJ, SJ, Bench 
press, chins, 3000 m 
running 
III 103 athletes*  
113 controls  
Cross-sectional RIA 
DXA 




SJ, CMJ, bench 
press, chins, 3000 m 
running, squats 
IV 57 athletes* 






V 94 athletes*  
86 controls  




Urinary steroids.   
UGT2B17 
*= The SOC study cohort, #=Glucuronide and sulphate metabolites measured.  
CMJ=countermovement jump, CYP=cytochrome P450, DXA=dual-energy X-ray absorptiometry, 
ECLIA=electrochemiluminescence immunoassay, FSH=follicle-stimulating hormone, GC-MS=gas 
chromatography-mass spectrometry, GC-MS/MS=gas chromatography-tandem mass spectrometry, 
IGF-I=insulin- like growth factor-I, IGFSD=age-adjusted IGF-I, IGFBP-1=IGF binding protein-1, 
LC-MS/MS=liquid chromatography–tandem mass spectrometry, LH=luteinizing hormone, 
SHBG=sex hormone-binding globulin, SJ=squat jump, SOC=swedish olympic committee, 
UGT=uridine-diphospho (UDP)-glucuronosyl transferase.  
 
5.1.1 Strengths and Limitations  
5.1.1.1 Study design  
The studies in this thesis are observational investigations, more specifically we implemented a 
cross-sectional study design. The main limitation in this type of study is that causality between 
different outcomes cannot be determined. Instead, cross-sectional studies can identify 
correlations between variables that can be further investigated. To determine causality, 
randomized controlled trials are often preferred. However, when conducting research including 
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elite level athletes, investigating anabolic hormones and the potential impact on physical 
performance and body composition the researcher is limited to the types of study designs that 
can be implemented. For example, conducting a randomized controlled trial, supplementing 
anabolic hormones and investigating the outcome in elite levels athletes would be highly 
unethical, since anabolic hormones such as androgens and IGF-I are considered to be doping 
agents and are prohibited from sports by WADA. In addition, our aim was to investigate 
endogenous anabolic hormones in relation to body composition and physical performance and 
possible factors that affect the endogenous androgen metabolism, for which a cross-sectional 
study design is appropriate.  
5.1.1.2 Study population  
Considering the study population, the sample size was limited by the unique population of 
interest, i.e. the number of active Swedish Female Olympic athletes available during the 
recruitment phase. In the end, a large proportion of athletes, 106 Swedish female Olympic 
athletes part of both the summer and winter games were included, being representative of the 
study group of interest. For the control group, the aim was to recruit healthy, untrained controls 
with no previous participation in elite level sport and with similar age and BMI as the athletes. 
In contrast to the athletes, the controls were recruited from the same geographical area 
(Stockholm) whereas the athletes were from different areas of Sweden.  
When recruiting a study population, one must be aware of possible selection bias. Even though 
we included a large proportion of Swedish Female Olympic level athletes this group may not 
be representative of all female Olympic level athletes. However, to our knowledge, this 
research project is the largest to date including female Olympic level athletes and a control 
group.   
5.1.1.3 Blood and urinary sampling  
In order to minimize the possible confounding effects of acute exercise, acute nutritional effects 
and diurnal rhythm, all blood and urinary samples were collected by a standardized procedure, 
in a fasted (overnight) and rested (no exercise on test day) state in the morning between 07.00-
10.00.  
5.1.1.4 Hormonal contraceptive use  
A previous study demonstrated that 47% of Swedish Female Olympic athletes used hormonal 
contraceptives (136). Since there is a limited number of Swedish Female Olympic athletes, 
excluding the athletes using hormonal contraceptives would have resulted in a significantly 
 
42 
lower number of participants, possibly resulting in loss of statistical power. Furthermore, in 
study IV, the aim was to evaluate the effects of hormonal contraceptive use on the urinary 
steroid profile. Therefore, both hormonal contraceptive users and non-users were included. 
Hormonal contraceptive use was evaluated by questionnaire including yes/no, if yes also type 
and duration of treatment was determined. In the statistical analyses, hormonal contraceptive 
use was taken into consideration to minimize possible confounding effects on endocrine 
parameters.  
5.1.1.5 The menstrual cycle   
Blood samples were taken randomly during the menstrual cycle. This is acknowledged as a 
limitation, however, due to logistical reasons, blood testing during a specific cycle phase was 
not possible. If recruitment had been cycle-dependent, the number of athletes able to participate 
in the studies with-in a reasonable time period would have been significantly lower. 
Furthermore, menstrual dysfunction is common among elite athletes (8, 134-136). Therefore, 
to more accurately reflect female athletes as a population, menstrual dysfunction was not 
considered an exclusion criterion. In the questionnaire participants were asked if they have 
regular menstruation and if not, bleeding pattern was established. Menstrual status was defined 
as: amenorrhea (absence of menstruations during at least the previous 3 months), 
oligomenorrhea (5-9 periods during the past year, occurring at interval > 6 weeks) or regular 
menstruation (periods at intervals of 22-34 days). In addition, in regularly menstruating women 
not using hormonal contraceptives, menstrual cycle phase was confirmed by analyses of serum 
hormones. Early follicular phase (cycle days 1–7) was defined as E2 <300 pmol/L, 
progesterone <5.1 nmol/L and low FSH and LH. Ovulatory phase was defined as E2 ≥300 
pmol/L, progesterone <5.1 nmol/L and LH higher than FSH. Luteal phase was defined as 
progesterone >16.9 nmol/L.  
 
5.2 ANALYTICAL METHODS  
 
Hormones were analyzed using mass spectrometry-based methods and/or immunoassays. The 
serum steroid profile was analyzed at the Endoceutics laboratory, Quebec City, Canada, using 
a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method (39, 40). 
IGF-I, IGFSD and IGFBP-1 were measured by an in-house RIA at the Karolinska Institutet 
(184, 185). The Urinary steroid profile was established by gas chromatography-mass 
spectrometry (GC)-MS, GC-MS/MS and LC-MS/MS (186-188) at the WADA accredited anti-
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doping laboratory at the Karolinska University Hospital Huddinge, Stockholm. FSH, LH, 
cortisol, insulin and SHBG were analyzed using standard methods accredited by the Karolinska 
University Hospital for clinical use. All separate laboratory analyses were conducted on one 
occasion for the combined group of athletes and controls.   
5.2.1 Mass spectrometry-based methods  
In this thesis, GC-MS, GC-MS/MS and LC-MS/MS methods were used to establish serum and 
urinary precursor androgens, active androgens and conjugated androgens. Briefly, these 
methods rely on initial separation through chromatography, followed by ionization of 
molecules. The ions then migrate through the mass analyzer allowing separation of ions 
according to their mass to charge ratio (m/z) using electromagnetic fields. Mass analyzers 
consists of a series of quadrupoles. In the first quadrupole, ions with a set m/z pass through. 
These ions (precursor ions) are then fragmented into product ions in a collision cell. In the next 
quadrupole, the same technique is applied filtrating a second m/z. This tandem mass 
spectrometry technique allows for better selectivity and sensitivity over single quadrupole 
instruments. The detector then registers and transforms the signal making it possible in the end 
to quantify the analyte of interest using different software programs.  
Since many compounds have the same molecular mass an initial separation step (differentiating 
samples depending on the physical characteristics) is needed before applying a mass 
spectrometric technique. LC separation is dependent on polarity, this is also true for GC but 
here boiling point has an even greater impact on retention time. Before applying the LC-
MS/MS technique, no sample preparation is required besides purifying the samples from 
proteins. For GC-MS and GC-MS/MS, extraction to organic solvent and derivatization is 
necessary, see section 5.2.1.2. GC-MS (study IV) and GC-MS/MS (study V) measures the 
glucuronide conjugated steroids and the unconjugated steroids, whereas LC-MS/MS (study I, 
II and III) can measure the glucuronide, sulfate and unconjugated fractions of steroids 
independently.  
5.2.1.1 Serum androgen profile  
Mass spectrometry-based methods are the reference method for serum steroid analysis 
although the advanced technical equipment and training required, as well as a relatively high 
cost meant that immunobased clinical methods were more prevalent in research for many years. 
In recent years, mass spectrometry analysis of steroids has evolved and become more available, 
making it possible to accurately measure several steroids in a single analysis (189). In this 
project, serum precursor androgens, active androgens and androgen metabolites were measured 
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by a validated LC-MS/MS method, ultra-high-performance LC-MS/MS, at the Endoceutics 
laboratory, Quebec City, Canada (39, 40, 182). The technique is still relatively expensive 
compared to immunobased methods. However, when using immunobased methods to measure 
androgens and T specifically, there is the major problem of antibody cross-reactivity between 
the structurally similar steroid hormones (precursors, active androgens and metabolites). Since 
LC-MS/MS does not rely on antibodies, cross-reactivity of steroid compounds is not a 
confounding factor. Furthermore, in the lower range, as for women, immunobased methods 
have low accuracy and sensitivity when measuring androgens, such as T. An additional 
limitation of immunobased measurement of steroid hormones is that the method is restricted to 
analyze one analyte at a time (4, 189, 190). LC-MS/MS, resulting in highly accurate 
measurements of androgen levels, is becoming the preferred method in sports endocrinology 
and many high impact journals only publish scientific papers where androgens have been 
established by mass spectrometry-based methods (189). Besides LC-MS/MS being more 
accurate compared to immunoassays, it also offers the possibility to measure the total androgen 
pool in women including precursor androgens, active androgens and androgen metabolites. 
Therefore, LC-MS/MS was the chosen method to analyze serum androgens in the studies 
included in this thesis. A limitation of the mass spectrometry technique is the lack of cross 
validation between laboratories. However, all serum samples included in the studies of this 
thesis were analyzed at the same laboratory.    
5.2.1.2 Urinary steroid profile  
The urinary steroid profile (T-G, EpiT-G, ADT-G, Etio-G, 5αAdiol-G, 5βAdiol-G) was 
analyzed applying the standard methods used at the WADA accredited doping control 
laboratory, Karolinska University Hospital, Huddinge, at the time of each study (GC-MS or 
GC-MS/MS) as previously described (186-188). Therefore, the method for establishing urinary 
steroids was changed from GC-MS in study IV to GC-MS/MS in study V. To be able to 
measure both sulphate and glucuronide conjugated steroids in urine in study II, an LC-MS/MS 
method was used. Furthermore, since the mass spectrometry method cannot distinguish 
between exogenous and endogenous androgens several biomarker ratios (T/E ratio, 
androsterone/etiocholanolone (A/Etio) ratio, androsterone/testosterone (A/T) ratio, 5αAdiol/E, 
5αAdiol/5βAdiol) have been determined to indirectly measure androgen abuse.  
Since the urine samples were stored at -18°C and were subject to several thaw cycles, there is 
the concern of possible degradation of steroids and bacterial contamination. Taking this into 
account, during the analytical process following standardized protocols, all samples are 
checked for bacterial contamination (i.e. presence of metabolites, 5α- and 5β-androstanedione 
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that can be produced by bacteria but not humans) (68). Before applying the GC-MS and GC-
MS/MS technique, sample preparation is required. Briefly this includes the following:  
Hydrolysis: Hydrolysis of the glucuronide conjugate by β-glucuronidase (from E.coli). Since 
the hydrolysis time for each steroid differs, an incomplete hydrolysis can result in a decreased 
A/T and A/Etio ratio (68). Hydrolysis is controlled by evaluating the ratio between d4-A-
glucuronide and d5-Etio (both added as surrogate internal standard) and if considered 
incomplete, the urine sample is prepared once more, controlling for pH, changing the 
hydrolysis time or increasing the amount of B-glucuronidase.  
Extraction: By adding an ether or N-pentane, lipophilic compounds such as unconjugated 
steroids can be extracted from water, hydrophilic compounds, salts and proteins.  
Derivatization: By adding chemical compounds, GC-separation and ionization is improved. 
An incomplete derivatization may result in a low A/T ratio (68). Derivatization is controlled 
for by monitoring the androsterone mono-trimethylsilyl derivates (TMS), which should be low 
compared to the fully reacted bis-TMS. If considered incomplete, additional derivatization 
reagent could be added and then heated further.  
By controlling for hydrolysis, derivatization and bacterial degradation in each sample the 
quality of the method is maintained. Different methodologies were used to establish the urinary 
steroid profile in this thesis and even though these methods produce similar results they are not 
identical. However, since only one method was used to establish urinary steroids for each study, 
when comparing values within each study the results should not be affected.  
5.2.1.3 Specific gravity  
The measured steroid concentrations are corrected for the dilution of the urine. Concentrated 
urine would otherwise overestimate the absolute concentration whereas diluted urine may 
underestimate the steroid concentration. In doping control samples, specific gravity, the ratio 
of weight of a volume of urine to the weight of the same volume of pure water at the same 
temperature, is used to adjust for urine dilution (191, 192). Each sample is corrected to a 
specific gravity of 1.020 according to: 𝐶𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 = 𝐶𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 ∗ 1.020 – 1/𝑆𝐺 – 1.  
5.2.2 Genotyping  
Genotyping for UGT2B17, UGT2B7, CYP17A1 was performed at the Department of 
Laboratory Medicine, KI. DNA was extracted from the whole blood samples using QIAamp® 
DNA Blood Mini kit (Qiagen). Genotyping was performed using TaqMan genotyping assays 
and Fast Real-Time polymerase chain reaction (rt-PCR) as previously described (45). Copy 
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number analysis of UGT2B17 was based on the ΔΔCT method using cycle threshold values 
compared to a reference gene (193). In study IV, albumin was used as reference gene and in 
study V, RNaseP. Individuals with a deletion in the UGT2B17 gene, del/del show signal for 
the reference gene (albumin or RNaseP) but no UGT2B17 amplification. Defining those with 
one copy vs two copies of the UGT2B17 gene is more complex due to possible signal overlap. 
Consequently, for some of the study participants UGT2B17 genotype could not be established. 
Therefore, in study IV, ins/del and ins/ins UGT2B17 individuals were combined as one group.  
5.2.1 IGF-I and IGFBP-1 
Since GH is released in a pulsatile manner, a single GH measurement does not reflect GH 
secretion in an accurate way. In contrast, IGF-1 levels are stable throughout the day and is 
suggested to mediate many of the anabolic effects of GH (5, 115). Therefore, we chose to 
analyze IGF-I and IGFBP-1, measured by in-house RIAs (184, 185). For detection limit, intra- 
and inter-assay coefficients of variations (CV) of these methods see table 5. IGF-I circulates 
bound to IGFBPs, therefore it is necessary to remove the effects of binding proteins in the 
analyses. Briefly, after separation of IGFBPs, by acid ethanol extraction and cryoprecipitation, 
IGF-I was determined by RIA. To minimize interference of remaining IGFBPs, des (1-3) IGF-
I was used as radio-ligand (184). IGFBP-1 was determined by RIA according to Póvoa et al 
(185). Circulatory IGF-I levels are age dependent, decreasing with age, taking this into account 
IGF-I values were also expressed as SD-scores (geometrical mean ± 2 SD) (IGFSD) calculated 
from the regression of the values of 247 healthy adults according to Hilding et al (112).   
It is difficult to compare immunoassay methods between laboratories, especially commercial 
IGF-I assays, due to the lack of standardization. However, in this thesis, all samples were 
analyzed for IGF-I using the same method performed at one laboratory. Therefore, difference 
observed between groups should be valid. In the context of doping, LC-MS/MS methods for 
analyzing IGF-I have been developed although this is not yet implemented as a standard 
method and immunoassays are still used.   
5.2.2 FSH, LH, SHBG, cortisol, Insulin  
Serum levels of FSH, LH, SHBG, Cortisol and Insulin were determined by 
electrochemiluminescence immunoassay, a standard method accredited by the Karolinska 
University Hospital. The lower limit of detection and intra- and inter-assay coefficient of 




Table 5. Methods, detection limits, intra- and inter-assay CV for hormonal analyses 
Analysis Manufacturer Method Lower DL Intra-assay CV Inter-assay CV 
FSH Roche  ECLIA 0.1 E/L 2.6%  3.6% 
LH Roche  ECLIA 0.1 E/L 1.2%  2.0%  
SHBG Roche ECLIA 0.35 nmol/L 1.3%  2.1% 
Cortisol Roche  ECLIA 1.5 nmol/L 1.7% 2.2% 
Insulin Roche  ECLIA 0.2 mIE/L 1.5% 4.9% 
IGF-I In house RIA 6 µg/L 4% 11% 
IGFBP-1 In house  RIA 3 µg/l 3% 10% 
DL=detection limit, ECLIA=electrochemiluminescence immunoassay, FSH=follicle-stimulating 
hormone, RIA=radioimmunoassay, IGF-I=insulin- like growth factor-I, IGFBP-1=IGFBP-1=IGF 
binding protein-1, LH=luteinizing hormone, SHBG=sex hormone-binding globulin.  
 
5.3 BODY COMPOSITION  
 
Dual-energy X-ray absorptiometry (DXA) is considered the current reference method for 
determining body composition (194, 195). It estimates BMD, lean body mass (skeletal muscle, 
internal organs and intestinal fat) and fat mass for the whole body and also for regional 
compartments such as the trunk and legs (195). Body composition (fat mass, lean body mass 
and BMD from the whole body) was measured for 65 athletes (61%) and 100 controls (85%) 
by DXA, a clinical standard method at the Karolinska University Hospital, Solna using the 
Lunar Prodigy Advance (GE Healthcare, Madison, WI, USA). The amount of fat in the trunk 
and legs (limit between defined as the line drawn from the upper margin of the iliac crest to the 
neck of the femur) was automatically calculated by the software. Upper/lower fat mass ratio 
was then established. Spinal BMD was established from the whole body DXA. Z-scores were 
calculated from the mean BMD and their SD values supplied by the manufacturer of the 
scanner (Z-score <-2SD is defined as low BMD). The reproducibility of the whole body BMD 
has been calculated to be <0.01 g/cm3 or 0.1xSD (183). Lean mass total % and lean mass legs 
% were calculated by dividing lean mass for the respective section with total mass and total 





5.4 PHYSICAL PERFORMANCE TESTS  
 
In addition, all athletes were offered to perform standardized physical performance tests part 
of the physical profile of the SOC at the Sports Institute, Bosön, Stockholm. Mainly power 
athletes participated in the physical performance tests. Furthermore, not all athletes did 
participate in all physical performance tests, which included squat jump (SJ) (n=59), 
countermovement jump (CMJ) (n=59), squats (n=50), bench press (n=45), chins (n=49) and 
3000 m running (n=20), (Figure 8). For SJ and CMJ maximum height (cm) was recorded using 
an infrared contact plate, IVAR equipment (IVAR Ltd. Tallinn, Estonia). SJ and CMJ are 
validated tests for measuring explosive power of the lower limbs (196) and bench press and 
squats are reliable tests for measuring strength (197).  
 




5.5 2D:4D RATIO  
 
Digit two (2D) and digit 4 (4D) were directly measured on the ventral surface of the hand, from 
the mid-point of the proximal crease of the proximal phalanx to the distal tip of the distal 
phalanx, using a Vernier digital caliper 0-150 mm (USA, Cocraft) with a precision of 0.01 (80). 
Digit measurements were made on both left and right hand and digit ratio calculated by dividing 
2D length by 4D length (Figure 5). The digits were independently measured by two raters. For 
rater A the intraobserver agreement was 0.90 for right hand and 0.90 for left hand. For rater B, 
the corresponding intraobserver agreement was 0.93 and 0.96, respectively. The inter-rater 
correlation was 0.87 for the right hand and 0.85 for left hand (198).  
 
5.6 STATISTICAL ANALYSES 
 
Statistical analyses were performed using Statistica version 13 (TIBCO Software inc (2018)) 
for study I, II, III and V and GraphPad PRISM 6.0® (GraphPad, San Diego, CA, USA) for 
study IV. The statistical methods used were selected depending on the distribution of the data 
and presented accordingly. Normally distributed data was analyzed using parametric statistical 
methods and not normally distributed data analyzed using non-parametric tests or parametric 
tests following transformation.  
Groups were compared employing the unpaired t-test or Mann-Whitney U-test. When 
appropriate, subgroups were compared using one-way analysis of variance (ANOVA) followed 
by Fisher, LSD post-hoc analyses, or Kruskal-Wallis ANOVA by ranks. Bonferroni correction 
was then employed when suitable. Two-way ANOVA was used when comparing groups, 
evaluating the possible interaction of hormonal contraceptive use and in study I analyses of 
covariance (ANCOVA) was used controlling for age and HC use. Categorical variables were 
compared by Chi-square test or Fisher’s exact test. Spearman’s rank order correlation or 
Pearson’s correlation were employed to assess correlation between variables. In study II, effect 
size for continuous variables was calculated using Cohen’s d and for categorical variables with 
Phi = √(Chi-2/n). 
In study I, a forward stepwise multiple regression analysis was employed to examine to what 
extent the physical performance tests (SJ and CMJ) could be explained by the serum androgens 
and lean mass variables. After fitting the regression equation, we examined the residuals by 
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Cook´s distance. Extreme cases were excluded and the model then reanalyzed. Hormonal 
contraceptive use was added to the regression models (SJ and CMJ) to evaluate potential 
interaction with androgens and lean mass variables. P-values <0.05 were considered 
statistically significant.  
 
5.7 ETHICAL CONSIDERATIONS  
 
Throughout this research project, ethical concerns have been part of the research process and 
been carefully taken into consideration. All studies were approved by the Regional Ethics 
Committee (Dnr 01-146 and Dnr 2011/1426-32) at the Karolinska Institute. The participants 
were volunteers and study participation could be cancelled at any time. When approaching the 
athletes, we took great care to highlight that participation in the study was voluntary. Controls 
that presented an interest in the study were given the same information. All participants 
received written information about the research project and written consent was obtained.  
In order to reduce the risk of disclosing sensitive personal information, data from the 
questionnaire and other variables such as body composition, digit ratio measurements, 
genotyping, urinary steroid profile or serum hormonal profile was de-identified. Since the study 
group of interest, i.e. Swedish Female Olympic athletes, is very specific, there is a higher risk 
of possible identification of study participants and we have constantly been aware of the ethical 
balancing act between research transparency and the importance of making it impossible to 
identify individual participants. Therefore, results have been presented and/or published at 
anonymous group level. Furthermore, the inclusion of study participants was done over several 
years (2011-2015) minimizing the risk of individual identification.  
All sample procedures were explained to the participants and blood samples were taken by 
medical staff, highly trained in the technique. Body composition was determined by DXA, an 
examination that does expose the individual to ionizing radiation. However, it is considered a 
safe procedure and the radiation dose is very low, corresponding to the normal background 
radiation over one day at sea level (194). All participants had the possibility to get their own 
results such as serum and urinary steroid hormone profile, genotyping results, body 
composition and digit ratio measurements. If any data or laboratory value was considered 
abnormal, a medical follow up was offered at the Department of Obstetrics and Gynecology, 
Karolinska University Hospital, Solna. 
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Study participants were genotyped to investigate certain genetic polymorphisms’ impact on the 
urinary steroid profile in women athletes. None of the genetic variations investigated are 
associated with disease or increased mortality. Furthermore, some results included in this thesis 
have been published with the aim to optimize the interpretation of the urinary steroid profile. 
Since the published data can be accessed by medical staff, coaches and athletes this information 
might be used to avoid being detected in doping controls. However, our research is focused on 
the anti-doping work and to not publish our results would be unethical, and lead to withholding 
information we believe can optimize the interpretation of doping tests in women.    
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6 RESULTS  
 
6.1 GENERAL CHARACTERISTICS OF FEMALE OLYMPIC ATHLETES AND 
CONTROLS (STUDY I-III) 
 
In table 6, general characteristics are presented for the female Olympic athletes and controls. 
There was no significant difference in age, BMI or hormonal contraceptive use between groups. 
However, the athletes were significantly taller (1.71±0.06 vs. 1.68±0.07 cm, p<0.001) and had 
a higher body weight (64.7±7.5 vs. 61.9±8.4 kg, p<0.01) compared to the controls. As 
expected, the athletes had significantly higher training hour per week compared to the controls.   
  
Table 6. General characteristics for female Olympic athletes and controls (SOC cohort).   
Parameters  Controls  Athletes   
n 117 106 
Age  26.2±5.5 26.0±5.6 
BMI  22.0±2.6 22.0±2.0 
HC use, n (%) 46 (39) 41 (39) 
MD, n (%) 3 (4)  15 (23)** 
Training (hours/week) 0.9±0.9 17.8±5.7*** 
Values presented as mean ± SD or number and percent. 
*p<0.05, **p<0.01, ***p<0.001. 
BMI=Body mass index, HC=hormonal contraceptive, MD=menstrual dysfunction. SOC=swedish 
olympic committee.  
 
Menstrual dysfunction was significantly more common in the athletes (Table 6). In the group 
of women with regular menstruations, not using hormonal contraceptives, there was no 
significant difference in cycle phases between groups (Table 7).  
 
Table 7: Cycle phase for regularly menstruating female Olympic athletes and controls not using 
hormonal contraceptives.  
Cycle phase * Controls (n, %) Athletes (n,%) 
Follicular Phase  24 (39 %) 24 (57 %) 
Ovulations Phase  18 (30 %) 8 (19%) 
Luteal Phase  19 (31 %) 10 (24 %) 
Total 61 (100 %) 42 (100 %) 
Number of subjects and percent presented.  
* Early follicular phase (cycle days 1–7) was defined as E2 <300 pmol/L, progesterone <5.1 
nmol/L and low FSH and LH. Ovulatory phase was defined as E2 ≥300 pmol/L, progesterone <5.1 
nmol/L and LH higher than FSH. Luteal phase was defined as progesterone >16.9 nmol/L. For 8 
athletes and 7 controls cycle phase could not be determined by hormonal analyses. 
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6.1.1 Hormonal contraceptives 
The majority of women were using contraceptives that inhibit ovulation. Furthermore, the 
distribution of different types of hormonal contraceptives was comparable between the female 
Olympic athletes and the controls (Table 8).  
Table 8:  Hormonal contraceptive type and contraceptive effects among female Olympic athletes 
and controls.   
Type of HC Controls  Athletes Substance Contraceptive effect 
HC use  46 (39 %) 41 (39 %) ---- ---- 
COCs 23 (50 %) 27 (66 %) E + P Inhibits ovulation  
Progestin -pill  3 (7 %) 4 (10 %) Desogestrel Inhibits ovulation    
Progestin implant 2 (4 %) 4 (10 %) Etonogestrel Inhibits ovulation  
Progestin IUD 3 (6 %) 1 (2 %) Levonorgestrel Endometrial effect   
Vaginal ring  10 (22 %) 1 (2%) E + P Inhibits ovulation  
“yes” HC, ns 5 (11 %) 4 (10 %) ---- ---- 
Inhibits ovulation 38 (83 %) 36 (88 %)        ---- ---- 
Number of subjects and percent presented. COCs=combined oral contraceptives, E=estrogen 
substance, ns=not specified, P=progestin, HC=hormonal contraceptives, IUD=intrauterine 
device.  
The majority of study participants were using COCs. The dose and type of substance for the 
COCs is presented in table 9. 
Table 9: Dose and type of substance in the COCs used by women Olympic athletes and controls.  
Dose and substance  Controls (n=23) Athletes (n=27) 
30 µg ethinyl estradiol  
0.15 mg levonorgestrel 
10 (44 %)  12 (45 %) 
20-30 µg ethinyl estradiol  
3 mg drosperinone 
7 (30 %) 10 (37 %) 
30-40 µg ethinyl estradiol 
0.05-0.125 mg levonorgestrel* 
0  1 (4 %) 
35 µg ethinyl estradiol  
0.25 mg norgestimat 
2 (10 %) 2 (7%) 
35 µg ethinyl estradiol 
2.0 mg cyproterone 
1 (4 %) 0 
30 µg ethinyl estradiol 
0.5-1.0 mg noretisterone 
1 (4 %) 2 (7%) 
1-3 mg estradiol  
2-3 mg diegonest 
1 (4%)  0 
1.5 mg estradiol 
2.5 mg nomegestrol 
1 (4%) 0 
Number and percent presented. COCs=combined oral contraceptives, n=number. *=triphasic.  
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6.2 SPORT CATEGORIES 
 
The athletes were divided into sport categories, power (n=63), endurance (n=29) and technical 
(n=14), depending on type of sport (Figure 7), as previously described by Hagmar et al (136).  
6.2.1 General characteristics, hormonal contraceptive use and menstrual 
dysfunction   
Age, BMI and training hours per week differed between the athlete groups. No significant 
differences were found regarding the frequency of hormonal contraceptive use or menstrual 
dysfunction between sport categories (Table 10).  
  
Table 10. General characteristics for female Olympic athletes of different sport categories (Power, 
Endurance, Technical). 
Parameters  Power Endurance Technical 
n 63 29 14 
Age  25.2±4.3 24.8±4.3 32.1±8.9 b***c*** 
BMI 22.1±1.9 21.3±1.4 23.3±3.0 c** 
HC use, n (%)   23 (37) 13 (45) 5 (36) 
MD, n (%) 7 (18) 6 (38) 2 (22) 
Training hours (h/w) 16.6±5.8 20.7±4.5 17.1±5.6 a**c* 
Values presented as mean ± SD or number and percent. 
*p<0.05, **p<0.01, ***p<0.001. 
a, power vs endurance; b, power vs technical; c, endurance vs technical 
BMI=body mass index, HC=hormonal contraceptives, MD=menstrual dysfunction.   
 
6.3 ANABOLIC HORMONES 
 
6.3.1 Anabolic hormones in athletes and controls  
Serum levels of the precursor androgens DHEA and 5-DIOL and the androgen metabolite Etio-
G were significantly higher among the athletes compared to controls, whereas estrone was 
significantly lower (Table 11). Serum T levels were within normal range for all study 
participants and no significant difference was observed between groups. Similar results were 
found for DHT (102 (85-150) vs. 102 (77-137) pg/mL) for controls and athletes, respectively. 
In addition, the athletes demonstrated significantly higher serum IGF-I, IGFSD and IGFBP-1 




Table 11. Endocrine profile for female Olympic athletes and female controls (SOC cohort).  
Endocrine profile   Controls  Athletes   
n 117 106 
E1, pmol/L 165.0 (95.4-273.3) 130.9 (85.1-211.9)* 
E2, pmol/L 174.4 (79.7-436.9) 130.7 (52.5-297.7) 
T, nmol/L 0.992±0.35 0.995±0.40 
SHBG, nmol/L 77.0 (54.0-139.0) 83.5 (58.0-125.0) 
DHEA, nmol/L 19.1 (15.3-27.8) 25.3 (15.6-36.8) ** 
5-DIOL, pg/mL 626±237 713±301* 
Etio-G, ng/mL 23.7 (17.5-33.3) 30.0 (19.7-41.9) * 
n 113 103 
IGF-I, µg/L^ 249.7±73.3 277.5±85.5* 
IGFSD^ -0.18±1.08 0.15±1.03* 
IGFBP-1, µg/L ^  49 (29-72) 62 (42-79)** 
Insulin, mIE/L^ 7.6 (5.6-9.8) 6.0 (4.5-8.1)*** 
Values presented as mean ± SD or median or interquartile range (25th–75th percentile). 
*p<0.05, **p<0.01, ***p<0.001. 
5-DIOL=androstenediol, DHEA=dehydroepiandrosterone, E1=estrone, E2=estradiol Etio-
G=etiocholanolone glucuronide, IGF-I=insulin-like growth factor-I, IGFBP-1=insulin-like growth 
factor binding protein-1, IGFSD=insulin-like growth factor-I age-dependent reference range, 
SHBG=sex hormone-binding globulin, SOC=swedish olympic committee, T=testosterone.  
^ = one athlete with diabetes type 1 excluded from analyses  
To convert: T nmol/L to ng/dL divide by 0.0347, DHEA nmol/L to ng/mL divide by 3.467, E1 
pmol/L to pg/mL divide by 3.699, E2 pmol/L to pg/mL divide by 3.671.  
 
Hormonal contraceptive use showed no statistically significant interaction when comparing 
serum androgens (DHEA, 5-DIOL, T, DHT, Etio-G) and IGF-I, IGFSD and IGFBP-1 between 
athletes and controls.  However, as expected, in the total population of athletes and controls, 
sex hormone levels were significantly lower in hormonal contraceptive users, whereas SHBG 
and IGFBP-1 were significantly higher (Table 12). 5-DIOL, IGF-I and IGFSD were 








Table 12. Serum hormone levels depending on hormonal contraceptive use in the total population 
of female Olympic athletes and controls (SOC cohort).   
Parameters  Non-HC users HC users 
n 136  87 
FSH, E/L 4.5 (3.2-6.1)  3.7 (0.8-6.0)** 
LH, E/L 6.5 (4.6-9.7) 2.8 (0.6-6.5)*** 
E2, pmol/L 315.7 (130.3-533.4) 176.6 (48.5-457.8)*** 
T, nmol/L  1.05±0.36  0.91±0.38** 
SHBG, nmol/L 70.0 (49.0-90.0)  136.0 (79.0-203.0)*** 
A4, nmol/L 5.0±1.8 3.5±1.4*** 
DHEA, nmol/L 23.3 (16.3-33.7) 21.2 (13.9-25.7)** 
IGFBP-1, µg/L 50.3±29.4 71.9±35.4*** 
Values presented as mean ± SD or median and interquartile range (25th–75th percentile). 
*p<0.05, **p<0.01, ***p<0.001. 
A4=androstenedione, DHEA=dehydroepiandrosterone, E2=estradiol, FSH=follicular-stimulating 
hormone, HC=hormonal contraceptives, IGFBP-1=insulin-like growth factor binding protein-1, 
LH=luteinizing hormone, SHBG=sex hormone-binding globulin, SOC=swedish olympic 
committee T=testosterone.   
To convert: T nmol/L to ng/dL divide by 0.0347, DHEA nmol/L to ng/mL divide by 3.467, E1 
pmol/L to pg/mL divide by 3.699, E2 pmol/L to pg/mL divide by 3.671, A4 nmol/L to ng/dL 
divide by 0.0349.  
 
6.3.2 Anabolic hormones depending on sport category  
Serum androgens and estrogens were comparable between groups. The power athletes had 
significantly higher IGF-I compared to technical athletes and significantly higher IGFSD 
compared to both endurance and technical athletes (Table 13). No statistically significant 
interaction was found for hormonal contraceptive use or age when comparing serum 
androgens, estrogens, IGF, IGFSD and IGFBP-1 between sport categories. 
 
Table 13. IGF-I and IGFSD female Olympic athletes of different sport categories (Power, 
Endurance, Technical). 
Endocrine profile  Power  Endurance Technical 
n 62 29 12 
IGF-I µg/L 293.6±78.4 264.4±94.3 221.5±76.2 b** 
IGFSD 0.37±0.88 -0.11±1.18 -0.44±1.06 a*b* 
Values presented as mean ± SD.  
*p<0.05, **p<0.01, ***p<0.001. 
a, power vs endurance; b, power vs technical; c, endurance vs technical 





6.4 2D:4D RATIO (STUDY II) 
 
The 2D:4D ratio right hand was significantly lower in the female Olympic athletes compared 
to female controls (Table 14). 2D:4D ratio left hand was comparable between groups.  
 
Table 14. 2D:4D ratio for female Olympic athletes and female controls.  
2D:4D ratio  Controls  Athletes   
n 117 104 
Right 2D:4D ratio  0.98±0.04 0.97±0.03*  
Left 2D:4D ratio  0.97±0.03 0.97±0.03 
Values presented as mean ± SD.  
*p<0.05, **p<0.01, ***p<0.001. 
2D:4D ratio=second to fourth digit ratio.  
 
6.4.1 Correlations between the 2D:4D ratio and the urinary steroid profile 
In the athletes, there were significant negative correlations between the 2D:4D ratio right hand 
and the urinary steroid metabolites, T-G (rs= -0.25, p <0.05), 5αAdiol-17G (r=-0.23, p<0.05) 
and 5βAdiol-17G (rs= -0.21, p<0.05), i.e. the lower digit ratio the higher androgen metabolites. 
There were no significant correlations between the 2D:4D ratio and serum androgen levels in 
the athletes or controls.   
 
6.5 BODY COMPOSITION  
 
6.5.1 Body composition in athletes and controls 
In table 15, body composition data is presented for all athletes and controls that participated in 
the DXA examination. As expected, the athletes had a more anabolic body composition with 







Table 15.  Body composition, including bone mineral density, body fat percent and lean body mass 
for female Olympic athletes and controls.  
Body Composition  Controls  Athletes 
n 100 65 
Total BMD g/cm2 1.15±0.07 1.25±0.08*** 
Spinal BMD g/cm2 1.01±0.10 1.11±0.11*** 
Z-score  0.35±0.86 1.60±1.02*** 
Body fat percent (%) 31.7±6.6 18.4±5.9*** 
Lean mass total (kg) 40.4±4.1 49.9±5.9*** 
Lean mass legs (kg) 13.6±1.6 17.3±2.2*** 
Values presented as mean ± SD.  
*p<0.05, **p<0.01, ***p<0.001. 
BMD=bone mineral density, kg=kilograms.  
 
6.5.2 Body composition depending on sport category  
The power athletes had the highest BMD and Z-score compared to both technical and 
endurance athletes. The technical athletes had the highest body fat percent whereas endurance 
athletes had the lowest body fat percent. Power and endurance athletes had significantly higher 
lean body mass compared to technical athletes. The endurance athletes had the highest 
percentage of total lean body mass compared to the other sport categories (Table 16).   
 
Table 16. Body composition, including bone mineral density, body fat percent and lean body mass 
for female Olympic athletes of different sport categories (Power, Endurance, Technical). 
Body composition  Power Endurance Technical 
n 42 18 5 
Total BMD g/cm2 1.28±0.07 1.19±0.07 1.17±0.05 a***b** 
Spinal BMD g/cm2 1.14±0.10 1.06±0.12 1.02±0.07 a* 
Z-score  2.04±0.85 0.82±0.85 0.76±0.64 a***b** 
Body fat percent (%) 19.3±5.3 14.4±4.7 25.3±6.0 a**c** 
Lean mass total (kg) 49.4±5.9 53.0±4.3 43.2±2.9 b*c** 
Lean mass legs (kg) 17.4±2.4 17.8±1.8 14.4±1.4 b*c** 
Values presented as mean ± SD.  
*p<0.05, **p<0.01, ***p<0.001. 
a, power vs endurance; b, power vs technical; c, endurance vs technical 





6.6 CORRELATIONS BETWEEN SERUM HORMONES AND BODY 
COMPOSITION  
 
6.6.1 Serum Androgens  
In the athletes, serum androgens were significantly positively correlated with total BMD (T 
(rs=0.31, p<0.05), DHEA (rs=0.28, p<0.05), A (rs=0.27, p<0.05)) and Z-score (T (rs=0.35, 
p<0.01), DHEA (rs=0.29, p<0.05), A (rs=0.30, p<0.05)). Furthermore, the precursor androgens 
5-DIOL and DHEA correlated positively to lean mass (Table 17). Similar findings were 
observed in the subgroup of athletes not using hormonal contraceptives (Table 17). Etio-G was 
significantly positively correlated to lean mass total (%) (rs=0.31, p<0.05) and lean mass legs 
(%) (rs=0.32, p<0.01).  
 
Table 17: Correlations between endogenous androgens and lean mass for female Olympic 
athletes not using HC and for the total group of athletes. 
 Athletes not using HC (n=41) Athletes total (n=65) 
Androgens DHEA 5-DIOL DHEA 5-DIOL 
Lean mass total rs = 0.44 
p = 0.004  
rs = 0.34 
p = 0.031  
rs = 0.27 
p = 0.03 
rs = 0.16 
p = 0.196 
Lean mass legs  rs = 0.49 
p = 0.001  
rs = 0.39 
p = 0.012 
rs = 0.33 
p = 0.007 
rs = 0.25 
p = 0.041 
Spearman correlation coefficient (rs) and p-values presented. Significant data marked in bold 
text. 5-DIOL=androstenediol, DHEA=dehydroepiandrosterone, HC=hormonal contraceptives.  
 
6.6.2 IGF-I 
In the total population of athletes and controls, IGFSD was significantly positively correlated 
with height (rs=0.14, p <0.05), total BMD (rs=0.23, p <0.01), Z-score (rs=0.23, p <0.01) and 
lean mass legs (kg) (rs=0.16, p <0.05). IGFBP-1 was positively correlated with spine BMD 
(rs=0.20, p <0.05), lean mass total (rs=0.20, p <0.05) and lean mass legs (rs=0.20, p <0.05) and 
negatively correlated with body fat percent (rs= -0.16, p <0.05). Insulin was negatively 
correlated to total BMD (rs= -0.20, p <0.05), Z-score (rs= -0.27, p <0.001) and lean mass total 
(kg) (rs=-0.20, p <0.01) and positively correlated to fat percent (rs=0.28, p <0.001).   
In the athletes, IGF-I and IGFSD were significantly positive correlated with height (rs = 0.21, 
p <0.05, rs=0.21, p<0.05, respectively). Furthermore, IGFBP-1 was significantly correlated 
with total BMD (rs=0.28, p= <0.05) and spine BMD (rs=0.28, p= <0.05).  
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6.7 CORRELATIONS BETWEEN SERUM HORMONES AND PHYSICAL 
PERFORMANCE  
 
6.7.1 Serum androgens 
In the athletes, DHEA and 5-DIOL were significantly positively correlated with SJ and CMJ 
(Figure 9). In addition, serum levels of Etio-G correlated positively with SJ (rs =0.26, p <0.05) 
and DHT with both SJ and CMJ (rs=0.27, p <0.05 and rs=0.39, p<0.01, respectively). In the 
subgroup of athletes not using hormonal contraceptives, most of these correlations remained 
significant (Table 18). Lean mass was positively correlated with SJ and CMJ. To evaluate the 
association between lean mass, the serum androgens and SJ and CMJ a multiple regression 
analyses was applied. The regression model demonstrated that the strongest factor predicting 
SJ was DHEA (β = 0.59, p <0.001), then lean mass legs (β = 0.42, p <0.001), in total accounting 
for 66 % of the variance in SJ. For CMJ, lean mass legs (β =0.65, p <0.001) and lean mass total 
(%) (β = 0.40, p <0.01) explained 52% of the variance. Hormonal contraceptives did not show 
any statistically significant interaction with lean mass or DHEA when added to the regression 
model.  
 
Table 18: Correlations between endogenous hormones, CMJ and SJ in female Olympic athletes 
not using HC and for the total group of athletes.  
 
 
Athletes not using HC Athletes total 
Performance test SJ CMJ SJ CMJ  
Number 
 
37 38 59 59 
DHEA rs = 0.37 
p = 0.026 
rs = 0.41 
p = 0.011 
rs = 0.39 
p = 0.002 
rs = 0.36 
p = 0.005 
5-DIOL rs = 0.28 
p = 0.093 
rs = 0.39 
p = 0.015 
rs = 0.34 
p = 0.009 
rs = 0.37 
p = 0.004 
DHT rs = 0.32 
p = 0.055 
rs = 0.47 
p = 0.003 
rs = 0.27 
p = 0.037 
rs = 0.39 
p = 0.002 
Spearman correlation coefficient (rs) and p-values presented. Significant data marked in bold 
text. 5-DIOL=androstenediol, CMJ=countermovement jump, DHEA=dehydroepiandrosterone, 
DHT=dihydrotestosterone, HC=hormonal contraceptives, SJ=squat jump. 
 
6.7.2 IGF-I 
In the athletes, serum levels of IGF-I were significantly positively correlated with SJ, whereas 
IGFBP-1 correlated positively with squats (Figure 9). In the subgroup of athletes not using 






Figure 9: Correlations of serum precursor androgens, IGF-I and IGFBP-1 with physical performance tests in 
female Olympic athletes. A) Relationship between DHEA and squat jump, B) between DHEA and 
countermovement jump, C) between 5-DIOL and squat jump, D) between 5-DIOL and countermovement jump, 
E) between IGF-I and squat jump and F) between IGFBP-1 and squats. 5-DIOL=androstenediol, 
DHEA=dehydroepiandrosterone, IGF-I=insulin-like growth factor-I, IGFBP-1=insulin-like growth factor binding 
protein-1. Reproduced from publication Serum androgen profile and physical performance in women Olympic 
athletes, E Eklund, B Berglund, F Labrie, Carlström K, Ekström L, Hirschberg AH, 2017;51(17):1301-8, copyright 
notice year 2017. With permission from BMJ Publishing Group Ltd.  
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6.7.3 2D:4D ratio and physical performance  
The 2D:4D ratio right hand was significantly negatively correlated with bench press (r= -0.36, 
p=0.015) and chins (rs= -0.28, p=0.050) and significantly positively correlated with 3000 m 
running performance time (r=0.51, p=0.022).  
 
6.8 THE URINARY STEROID PROFILE IN FEMALE ATHLETES AND 
CONTROLS (STUDY IV AND V) 
 
6.8.1 General characteristics of female athletes (study IV) 
In total 79 female athletes participated in the study with a mean age of 26, ranging from 18-45 
years. Hormonal contraceptive use was evaluated by questionnaire (n=57) or from the 
anonymous doping control form (n=22). In total, 25 (32 %) of the athletes used hormonal 
contraceptives, the majority taking COCs (n=23). Progestin only contraceptives (progestin 
intrauterine device or desogestrel) were used by two women.     
 
6.9 THE IMPACT OF GENETICS AND HORMONAL CONTRACEPTIVES ON 
THE URINARY STEROID PROFILE  
 
6.9.1 Genetics   
The allele frequencies for the investigated polymorphisms (UGT2B17, UGT2B7 and CYP 
17A1) were similar for study IV and study V and in line with previously published data in 
Caucasians.  
In study IV, the UGT2B17 genotype had a significant impact on the urinary T levels as well as 
the T/E ratio in female athletes. The UGT2B17 del/del individuals excreted significantly lower 
levels of urinary T and had a significantly lower T/E ratio compared to the combined ins/del 
and ins/ins group. Furthermore, the 5α-diol/5β-diol ratio was significantly higher in the 
UGT2B17 del/del athletes (Table 19). The A/Etio ratio and A/EpiT ratio did not differ between 
groups. These results were verified in study V, both in female Olympic athletes and female 
controls. In addition, there were significant differences in U-T and T/E between all UGT2B17 





Table 19: Comparison of the urinary steroid profile depending on UGT2B17 genotype in female 
athletes and controls.  
Study IV, Female athletes (Del/Del n=6, Ins/Del n=40, Ins/Ins n=22) 
UGT2B17 Del/Del Ins/Del + Ins/Ins p-value 
U-T ng/mL 0.66 (0.46-1.5) 5.4 (0.74-19.4) *** 
U-EpiT ng/mL 4.9 (1.8-21.5) 6.6 (1.2-25) ns 
T/E 0.15 (0.09-0.3) 0.8 (0.8-3.4) *** 
5α-diol/5β-diol 0.99 (0.45-1.8) 0.32 (0.06-1.0) ** 
Study V, Female Olympic athletes (Del/Del n=9, Ins/Del n=45, Ins/Ins n=39) 
UGT2B17 Del/Del  Ins/Del Ins/Ins  
U-T ng/mL 0.43 (0.29-0.52) 4.24 (2.25-5.82) 6.03 (4.24-10.74) a***b***c*** 
U-EpiT ng/mL 5.83 (3.15-12.56) 6.55 (3.17-11.41) 6.03 (3.96-10.73)  
T/E ratio  0.06 (0.05-0.09) 0.64 (0.40-1.02) 1.18 (0.70-1.71) a***,b***,c*** 
5α-diol/5β-diol  0.76 (0.67-1.32) 0.27 (0.17-0.44) 0.24 (0.12-0.41) a***,b*** 
Study V, Female controls (Del/Del n=8, Ins/Del n=45, Ins/Ins n=32) 
UGT2B17 Del/Del Ins/Del Ins/Ins 
U-T ng/mL 0.69 (0.48-0.87) 6.41 (4.06-10.20) 14.41 (5.64-19.78) a**b***c** 
U-EpiT ng/mL 13.83 (8.86-22.07) 10.81 (5.52-14.93) 13.06 (6.50-23.68)  
T/E ratio  0.05 (0.03-0.08) 0.66 (0.43-1.01) 0.90 (0.69-1.23) a***,b***,c* 
5α-diol/5β-diol  0.70 (0.51-1.05) 0.35 (0.23-0.51) 0.27 (0.14-0.58) a*,b** 
Study IV, median and range. Study V, median and interquartile range (25th-75th percentile). Urinary 
steroids adjusted for specific gravity.  
*p<0.05, **p<0.01, ***p<0.001.   
a, Del/Del vs Ins/Del: b, Del/Del vs Ins/Ins and c, Ins/Del vs Ins/Ins.  
5α-diol=5α-Androstane-3α,17β-diol 5β-diol=5β-Androstane-3α,17β-diol ns=non-significant, T/E 
ratio=testosterone/epitestosterone ratio, U-EpiT=urinary epitestosterone, U-T=urinary testosterone. 
 
In study IV, the UGT2B7 polymorphism was not associated with any significant difference in 
urinary steroid levels. For the CYP17A1 polymorphism, in the subgroup of hormonal 
contraceptive users, individuals with the CC+CT genotype had significantly higher urinary 
EpiT (5.6 (1.6–12.9) vs. 2.2 (0.91–5.9) ng/mL, p<0.01, respectively) and T levels (6.2(2.3–
14.4) vs. 2.4 (0.74–9.4) ng/mL, p<0.05, respectively) compared to the TT genotype group. In 
the athletes not using hormonal contraceptives, there were no significant differences in urinary 





6.9.2 Hormonal contraceptives   
In study IV, female athletes using hormonal contraceptives had significantly lower urinary 
EpiT levels compared to non-users (4.9 (range: 0.90–12.9) ng/mL vs. 8.2 (range:1.5–25.0) 
ng/mL, p <0.0005, respectively)). When removing individuals with a UGT2B17 deletion (n=6) 
the T/E ratio was significantly higher in hormonal contraceptive users compared to non-users 
(0.9 (range: 0.39–3.4) vs. 0.7 (range: 0.08–2.8) ng/mL, p<0.05, respectively)) (Figure 10). The 
A/EpiT was significantly higher in hormonal contraceptive users. These findings were verified 
in the athletes and controls included in study V (data not shown). In addition, in both athletes 
and controls after excluding del/del individuals, U-T levels were significantly lower in 
hormonal contraceptive users (3.3 (1.7-5.4) and 5.5 (4.1-10.2) ng/mL) compared to non- users 
(5.1 (2.7-9.0) and 7.0 (4.3-16.3) ng/mL, p <0.05 and p <0.001, respectively).  
 
 
Figure 10: Urinary epitestosterone levels in female athletes not using hormonal contraceptives (no HC) compared 
to those taking hormonal contraceptives (HC) and Testosterone/Epitestosterone glucuronide ratio in female 
athletes depending on HC use after removing the UGT2B17 del/del individuals (n=6). Reprinted from Frontiers 
in Endocrinology, vol 5, article 50, p 1-6; copyright 2014; Open access.CC-BY license (181). 
 
6.10 COMPARISON OF THE URINARY STEROID PROFILE BETWEEN FEMALE 
OLYMPIC ATHLETES AND CONTROLS (STUDY V) 
 
The female Olympic athletes demonstrated significantly lower urinary androgen metabolite 
levels compared to the controls, although serum androgen levels were comparable. The A/Etio 
ratio was significantly lower in the athletes than the controls, whereas all other ratios part of 
the ABP were comparable between groups as well as serum T, SHBG and FAI (Table 20). In 
the subgroup of athletes and controls not using hormonal contraceptives similar results were 
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found (data not shown), except for cortisol being higher in the subgroup of athletes not using 
hormonal contraceptives compared to controls not using hormonal contraceptives (474.1 ± 
131.2 vs. 376.4 ± 108.0, p=0.004). 
 
Table 20: Serum hormones and urinary androgen metabolites in female Olympic athletes and 
controls. 
Serum hormones  Controls Athletes  
n 86 94 
T (nmol/L) 1.0 ± 0.37 0.99 ± 0.40 
SHBG (nmol/L) 80.5 (62.0-129.0) 82.0 (57.0 -117.0) 
FAI 1.1 (0.6-1.8) 1.1 (0.6-1.9) 
Cortisol (nmol/L) ^ 516.0 ± 263.6 579.0 ± 216.3 
U-androgen metabolites  
U- Testosterone (ng/mL) 6.90 (4.27-14.30) 4.59 (2.25-8.00)*** 
U- Epitestosterone (ng/mL) 10.99 (6.34-19.64) 6.09 (3.60-11.41)*** 
U- Androsterone (ng/mL) 3386 (2390 -5627) 2178 (1278 -3554)*** 
U- Etiocholanolone (ng/mL) 3647 (2504 -4838) 2762 (1769 -4139)** 
U- 5αAdiol (ng/mL) 33.4 (21.3-52.7) 19.6 (12.4-30.0)*** 
U- 5βAdiol (ng/mL) 86.8 (53.0-197.1) 84.5 (39.1-132.8)* 
T/E ratio ^ 0.7 (0.5-1.1) 0.7 (0.4-1.3) 
A/Etio ratio 1.0 (0.8 -1.3) 0.8 (0.6-1.1)* 
A/T ratio  458 (294-767) 428 (329 -696) 
5αAdiol/E 3.2 (1.9-5.0) 3.6 (2.4-4.8) 
5αAdiol/5βAdiol 0.3 (0.2-0.6) 0.3 (0.2-0.5) 
Values presented as mean  SD or median and interquartile range (25th-75th percentile).  
*p < 0.05, **p < 0.01, ***p < 0.001. 
5αAdiol=U-5α-Androstane-3α,17β-diol, 5βAdiol=U-5β-Androstane-3α,17β-diol, 
A=androsterone, E=epitestosterone, Etio=etiocholanolone, FAI=free androgen index, SHBG= 
sex hormone-binding globulin, T=testosterone.  
^= Two-way ANOVA indicated that HC use interacted with the comparison between groups.  
 
6.10.1 Correlations between training load and the urinary steroid profile  
As expected, the athletes had significantly higher training hour per week compared to controls 
(18.2 ±5.8 h vs. 0.7 ±0.8, p <0.001, respectively). In the athletes, urinary steroid metabolites: 
androsterone (rs=-0.28, p=0.007), epitestosterone (rs=-0.22, p=0.034), 5αAdiol (rs=-0.31, 
p=0.002) and testosterone (rs=-0.24, p=0.026), were negatively correlated with training 
frequency (hours per week).   
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7 DISCUSSION  
 
In this thesis, anabolic hormones were compared between female elite athletes and controls, 
between sport categories and in relation to body composition and physical performance. The 
2D:4D ratio was also investigated in athletes and controls and in relation to serum and urinary 
androgen levels and physical performance. Furthermore, the impact of hormonal 
contraceptives and genetic variation on the urinary steroid profile was examined in female elite 
athletes and the urinary steroid profile compared between athletes and controls and in relation 
to training hours per week. In study I, precursor androgens were significantly higher in the 
athletes compared to controls and were related to a more anabolic body composition and 
increased physical performance in the athletes. In study II, the 2D:4D ratio was found to be 
lower in the athletes than controls and related to the urinary steroid profile and physical 
performance, but not to serum androgen levels. In study III, the athletes demonstrated higher 
IGF-I, IGFSD and IGFBP-1 compared to controls and power athletes had the highest IGFSD 
compared to endurance and technical athletes. IGF-I was positively associated with lean mass 
and certain physical performance tests. In study IV, hormonal contraceptive use was 
associated with significantly lower urinary EpiT-G levels and when removing del/del 
individuals the T/E ratio was higher in athletes using hormonal contraceptives. The UGT2B17 
deletion polymorphism and CYP17A1 promoter polymorphism also influenced the urinary 
steroid profile in female athletes. In study V, athletes were found to excrete approximately 
30% lower urinary androgen metabolites compared to controls, although serum levels were 
comparable. In the athletes, the urinary steroid metabolites were negatively correlated with 
training hours per week.  
 
7.1 ANABOLIC HORMONES IN FEMALE ELITE ATHLETES AND CONTROLS  
 
There is limited previous knowledge on endogenous androgens and IGF-I in female elite 
athletes compared to untrained controls. In contrast to most previous studies, we measured 
serum androgens using LC-MS/MS allowing for precise determination of androgen levels in 
women and the possibility to measure precursor androgens, active androgens and androgen 
metabolites. In study I, serum T levels were within the normal range for all participants and did 
not differ significantly between groups, in agreement with two previous publications (160, 
161). However, Rickenlund et al (138) found higher T levels in a subgroup of endurance 
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athletes with menstrual disturbance than in sedentary controls. In our population, the subgroup 
of athletes with menstrual dysfunction had significantly higher serum Etio-G compared to 
athletes with regular menstruation and controls.  
Furthermore, we found significantly higher serum levels of precursor androgens (DHEA, 5-
DIOL) and the androgen metabolite (Etio-G) in the athletes compared to controls. In women, 
most active androgens are synthesized by transformation of precursor androgens, such as 
DHEA, in the target tissue (20, 23, 25, 26). It is possible that the higher levels of precursor 
androgens found in the athletes result in more substrate for intra-cellular transformation to 
active androgens able to exert anabolic effects. To further examine the anabolic hormonal 
profile in female elite athletes, IGF-I, age-adjusted IGF and IGFBP-1 were investigated in 
study III. The higher IGF-I and IGFBP-I levels in our population of female athletes compared 
to the controls is in agreement with Roli et al (178) reporting higher calculated IGF-I reference 
ranges in 58 female volleyball players compared to that of a female reference population. In 
contrast, others have reported no significant difference in IGF-I levels between female athletes 
and controls, although the study populations were small (176, 179).  
The underlying mechanism for our observed findings of increased endogenous precursor 
androgens and IGF-I in the athletes in not known and owing to the cross-sectional study design, 
causality cannot be determined. However, potential explanations for our findings include 
exercise-induced changes of hormones, nutritional changes, doping or a genetic predisposition. 
Acute exercise has been shown to temporarily elevate DHEA and other androgens, although 
these return to baseline values within hours (24). IGF-I levels have been observed to increase, 
decrease or show no change in response to acute and chronic exercise (110, 121, 177, 178, 180, 
199, 200). Although the anabolic hormonal changes due to exercise are not completely 
clarified, we performed the blood sampling in a rested state, thereby excluding the possible 
acute exercise changes in hormone levels. Additionally, even though IGF-I levels are known 
to increase in response to amino acids/protein, whereas IGFBP-1 decrease, acute nutritional 
effects are not likely to have influenced our results, since all blood samples were collected in a 
fasted state. On the other hand, chronic energy deficiency reduces IGF-I levels (107, 201) and 
increases IGFBP-1 (109, 144, 201). Although this condition is common among elite athletes 
(126), the finding of higher IGF-I levels in the athletes compared to controls argues against 
chronic energy deficiency having an impact on our results.  
Androgen supplementation affects urine and especially serum androgen levels in women (61). 
Anabolic agents such as AAS, GH and IGF-I are used as doping agents among elite athletes 
(7, 166, 171). We acknowledge that we did not evaluate the potential misuse of GH or IGF-I 
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in our study population. However, all female athletes that participated in the studies are 
regularly included in doping control tests. The urinary steroid profile of endogenous AAS and 
synthetic AAS were analyzed for all participants and none demonstrated atypical findings. 
Therefore, we believe that doping was not the reason for higher precursor androgens and IGF-
I and IGFBP-1 in the athletes.  
Speculatively, our observed findings of higher precursor androgens and IGF-I and IGFBP-1 in 
the female athletes compared to controls may reflect a genetic predisposition for a more 
anabolic hormonal constitution. For IGBP-1 and particularly IGF-I concentrations there is a 
strong genetic influence, determining 36% and 63% of the variance, respectively (202). 
Furthermore in athletes, endogenous IGF-I levels have been shown to be stable with low intra-
individual variability (14-16%) (203). The heritability of T and SHBG have also been estimated 
to be high. In post-menopausal sisters and twins, the heritability of T and SHBG was 39% and 
56 %, respectively (204). Another study including women >19 y, not using exogenous 
hormones or being pregnant and with intact ovaries, found that total, free T and SHBG showed 
moderately to high heritability estimates (25-56%) after adjusting for age, BMI, diabetes, 
current smoking and menopausal status (205). Furthermore, in a subset of female twins not 
using hormonal contraceptives, included in the follicular phase of the menstrual cycle, the T 
level heritability estimate was 51% (206). Additionally, PCOS a common condition among 
female elite athletes, is suggested to have a genetic association (136, 138, 142, 207). PCOS is 
also a known cause for menstrual dysfunction among female Olympic athletes and athletes 
with PCOS have demonstrated both higher T and DHEA-S compared to regularly menstruating 
elite athletes (136). PCOS was not evaluated in our study population, however as reported in 
study I, menstrual dysfunction was more common among female athletes than controls and the 
athletes demonstrated higher precursor androgen levels. Considering this, there is the 
possibility of some of the athletes included in this study having PCOS.  
7.1.1 Anabolic hormones depending on sport category  
Although we hypothesized higher androgens levels among power athletes compared to 
endurance and technical athletes no significant differences in androgen levels were observed 
between groups. In a large study by Bermon et al (142), it was reported that T and DHEA-S 
were higher in athletes participating in throwing and jumping events compared to long distance 
events. Furthermore, athletes participating in strength, explosive and power sports have been 
found to have higher precursor androgens compared to long distance runners (19). In our 
population of power athletes, age-adjusted IGF-I levels were highest compared to the other 
sport categories. In agreement, higher serum IGF-I levels have been observed in gymnast 
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compared to runners (176). However, in a large study by Healy et al (14), swimmers and cross-
country skiers were reported to have the highest IGF-I levels. We chose to divide the athletes 
into sport categories of power, endurance, technical disciplines with reference to a previously 
published study by Hagmar et al (136). However, the discrepancy between our findings and 
previous reports may be due to the heterogeneity of included sports in each sport category. 
Furthermore, the number of participants in each sport category was limited and our results 
should therefore be interpreted with caution.  
 
7.2 ENDOGENOUS ANABOLIC HORMONES, BODY COMPOSITION AND 
PHYSICAL PERFORMANCE  
 
7.2.1 Body composition  
The existing literature on the relationship between endogenous anabolic hormones, such as 
androgens and IGF-I and body composition in female elite athletes is very limited. Several 
factors are suggested to regulate body composition in female athletes such as exercise, nutrition 
and anabolic hormones (4, 12, 208). For example, endogenous androgens promote bone 
formation, have anabolic effects in muscle tissue and stimulate the erythropoiesis (4, 149-151), 
whereas IGF-I stimulates protein synthesis in human skeletal muscle and has anabolic effects 
on adult bone remodeling (107, 108). These effects may be beneficial for athletic performance 
and possibly reduce the risk of injury in elite athletes. In this thesis, we report new findings on 
the relationship between endogenous anabolic hormones, body composition and physical 
performance in elite female athletes.  
Not surprisingly, we found that the female athletes had significantly higher BMD and lean mass 
and lower body fat percent compared to untrained female controls. There is substantial 
evidence that athletes demonstrate higher BMD and lean mass compared to sedentary controls 
(138, 209-211). In agreement with our results with power athletes demonstrating the highest 
BMD, high impact sports such as volleyball and soccer are associated with higher BMD 
compared to low impact sports such as swimming (212). Increased mechanical loading leads 
to structural adaptations that stimulate bone formation and improve bone strength (207). The 
intense training regimes undertaken by athletes may therefore explain the differences in body 
composition observed between athletes and controls (208, 210, 212). Furthermore, exercise 
generally promotes an increase in muscle mass and a decrease in fat mass i.e. leanness (high 
muscle/lean mass, low fat mass), having a positive influence on physical performance in many 
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sports (213). However, it is highly likely that these adaptations to exercise are driven by the 
effects of androgens and other anabolic hormones such as IGF-I.  
In support of an anabolic role of endogenous androgens for BMD and lean mass in female 
athletes, we found significant positive correlations between precursor androgens, T and BMD 
as well as between DHEA, 5-DIOL and Etio-G and lean mass. These findings remained in the 
subgroup of athletes not using hormonal contraceptives. Comparable results have been 
observed in postmenopausal women (158, 159),  in non-athletic PCOS women (145) and in a 
small cohort of female athletes (138). Furthermore, in the total population of athletes and 
controls, we found that endogenous IGF-I and IGFBP-1 were positively associated with BMD 
and lean body mass. Others have reported a positive correlation between IGF-I and body weight 
(177), BMD and lean mass (176). However, most previous assumptions on IGF-I anabolic 
effects on body composition in athletes are extrapolated from studies investigating exogenous 
GH and IGF-I in GH-deficient adults (164, 167). In contrast, in recreational athletes IGF-I 
supplementation resulted in no significant change in body composition (173). Interestingly, in 
muscle cells, a locally produced IGF-I isoform (MGF) is expressed as a result of mechanical 
stimuli. This IGF-I isoform increases with exercise and is believed to be important for satellite 
cell activations and muscle regeneration (121). The role of circulating vs. locally produced 
IGF-I was not evaluated in this thesis, however theoretically both higher circulating IGF-I and 
locally produced IGF-I, the latter as a result higher training load in the athletes, may result in 
positive anabolic effects on muscle tissue.  
7.2.2 Physical performance  
In support of a role of endogenous anabolic hormones for physical performance in female 
Olympic athletes we observed significantly positive associations between DHEA, 5-DIOL and 
DHT with SJ and CMJ performance. Multiple regression analyses showed that DHEA was the 
strongest factor predicting SJ, whereas lean mass was the most significant determinant for 
CMJ. Previous investigations on the relationship between endogenous androgens and physical 
performance have demonstrated a positive association between serum T and CMJ in 22 female 
athletes (16). Furthermore, in a large observational study by Bermon et al (19) female athletes 
with the highest tertile of free T levels had a competitive advantage in certain sport events (400 
m, 400 m hurdles, 800 m, hammer throw, pole vault) compared to female athletes in the lower 
free T tertile.  
We found no significant correlations between serum T and physical performance in our cohort 
of female Olympic athletes. However, in women, intracellular transformation of DHEA 
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accounts for approximately 50 % of the T production and DHEA is therefore suggested to be 
the most important precursor androgen in women (26, 214). This is in contrast to men where 
the majority of endogenous T production takes place in the testis, whereas very small amounts 
are produced from DHEA (148). In male athletes, DHEA supplementation has not 
demonstrated any anabolic effects (215). It is possible that the same relationship is true for 
women with supra physiological T levels, whereas for women with endogenous T levels within 
the normal range (such as our study cohort), DHEA may be more important for athletic 
performance (216). This is supported by our findings of significant positive correlations 
between DHEA and physical performance. This hypothesis is further strengthened by muscle 
biopsy studies in non-athletic women, where adding DHEA resulted in significantly increased 
intramuscular T but not estradiol. Furthermore, intramuscular estradiol, T, DHT and DHEA 
were independent predictors of muscle strength and power (217).  
Further supporting a significant role of endogenous androgens for increased muscle mass and 
athletic performance is the 15-times higher endogenous T levels and the superior physical 
performance of men compared to women and pre-pubertal boys and girls (218). Since 
exogenous T and endogenous T have identical chemical structures and similar biological 
effects (4), studies evaluating the effects of T supplementation are also of interest. In men, T 
supplementation results in a dose-dependent increase in muscle mass and strength (4, 153, 219) 
and there is a growing body of evidence for similar findings in postmenopausal women (156) 
and premenopausal healthy, trained, women (18). Further solidifying the positive anabolic 
effects of androgens in athletes, is the use of AAS with reports of increased strength and 
training ability (7). Investigations on the use of AAS in female athletes is  limited, however 
documentation of the experiments performed in the DDR, revealed that athletes were subjected 
to AAS from an early age and that the performance enhancing effects were especially 
prominent in women (15). In addition, there is an overrepresentation of hyperandrogenic 
conditions such as PCOS (136, 220-223) and 46 XY DSD (142) among female athletes 
compared to the general population. Moreover, for women with DSD a reduction of T levels 
resulted in a 5-7 % decrease in physical performance (147). Interesting data is also emerging 
from studies investigating the effects of altered anabolic hormonal levels on muscle volume 
and physical performance in transgender men and women. In transgender men (female to male 
transgender), T supplementation, resulting in increased T levels in adult male range, 
significantly increased both muscle mass, hemoglobin levels and grip strength (224, 225), 
whereas in transgender women (male to female) a reduction in T levels from adult male to 
female range reduced muscle mass by 9.4 % and hemoglobin levels by 14 % (224). More 
recently, Wiik and colleagues (157)  observed a robust increase in muscle volume and muscle 
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strength, the latter by approximately 12 % following 12 months of cross-hormone treatment in 
transgender men. In transgender women a slight decrease in muscle mass was evident, whereas 
muscle strength was maintained.    
An alternative explanation for the sex difference in athletic performance between men and 
women are anabolic effects of endogenous GH and IGF-I. GH secretion is however higher in 
women compared to men (4) whereas IGF-I is comparable between sexes (111). To our 
knowledge no previous studies have investigated the role of endogenous IGF-I for physical 
performance in female elite athletes. However, in untrained women, IGFBP-2 has been 
associated with peak oxygen uptake (174). In contrast, in adolescent girls, IGF-I was not related 
to physical fitness measured by aerobic performance (175). In our population of athletes, we 
did observe significant positive correlation between IGF-I and IGFBP-1 and SJ and squat 
performance, respectively. These results may support an anabolic role of IGF-I in female 
athletes however the correlations were weak.  
The majority of evidence for the positive anabolic effects of GH originates from studies 
investigating GH and IGF-I supplementation to GH deficient adults (164, 166, 167), whereas 
comparable findings in healthy subjects and elite athletes have been proven difficult to 
reproduce (166, 168, 169, 226). The exception is the study by Meinhardt et al (172) where GH 
supplementation was given to recreational athletes resulting in a slight improvement in sprint 
performance in men but not in women. These effects were significantly amplified in male 
participants receiving T supplementation in addition to GH. Androgens and estrogens are 
suggested to be connected to GH/IGF secretion. Androgens have been shown to increase GH 
and IGF-I secretion following aromatization to estrogen (114, 115), and estrogen 
supplementation depending on distribution route can increase or decrease serum IGF-I levels 
(116). In elderly women, DHEA supplementation increases IGF-I levels (227). However, this 
has not yet been replicated in recreational female athletes, possibly due to a small study sample 
or short durations of supplementation (228).   
Taking both previously published findings and the results presented in this thesis, we suggest 
that endogenous androgens, as well as endogenous IGF-I play a role for increased muscle mass 





7.3 THE 2D:4D RATIO IN FEMALE ELITE ATHLETES  
 
In the largest study to date including only top-elite female athletes, we found that the 2D:4D 
ratio right hand was lower in the female Olympic athletes compared to the control group, 
suggesting a higher prenatal androgen exposure in the athletes. No significant difference was 
observed in the left 2D:4D ratio. This is in line with previous work primarily in male athletes 
(97, 98, 100), and it has been suggested that the right 2D:4D ratio is more representative of 
prenatal androgen exposure (79). In agreement with our results, previous studies investigating 
the digit ratio in female athletes at national level (99), college tennis players (100), youth 
handball players (98) and non-elite athletes (97) have found a lower 2D:4D in the athletes 
compared to controls.  
In addition, we found significant correlations between the 2D:4D ratio and increased strength 
and faster 3000 m running times in the athletes. The few previous studies that have investigated 
the digit ratio and athletic performance in female athletes, have found faster skiing times (103), 
faster rowing times (102), greater running performance (229) and better national fencing level 
(101) to be related to a lower 2D:4D ratio. Taken together, this supports a role of prenatal 
androgen exposure for physical performance in female elite athletes.  
The explanation for the association between the 2D:4D ratio and athletic ability is not 
elucidated. Several plausible mechanisms have been proposed such as a possible connection 
between the 2D:4D ratio and adult serum androgen levels, genetic variants in the AR-receptor 
and other genes coding for androgen metabolizing enzymes (80, 104). There is increasing 
evidence of the positive effects of endogenous and exogenous androgens on physical 
performance in women and female athletes (8, 16, 18, 136, 182). However, in agreement with 
our findings in study II, recent studies have found no robust evidence for an association 
between the 2D:4D ratio and adult serum androgens (104, 105). The role of genetic variations 
in the AR-receptor in relation to the 2D:4D ratio have also been investigated, with the 
conclusion that the digit ratio is not associated with the AR-receptor (104, 106). Polymorphism 
in other genes coding for enzymes important for T metabolism and function, such as CYP19A1 
(aromatase), SRD5A2 (5α-reductase) and SHBG genes (SHBG), have recently been evaluated 
showing no evident associations with the 2D:4D ratio (104). Even so, studies have indicated 
that the 2D:4D ratio is a heritable trait and that the 2D:4D ratio may be associated with other 
genetic factors (230-233).  
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Interestingly, we were first to demonstrate that the 2D:4D ratio was negatively correlated to 
certain urinary steroid glucuronide metabolites (T-G, 5αAdiol-17G, 5βAdiol-17G). As 
previously described, the conjugation of androgens by androgen metabolizing enzymes (phase 
II enzymes i.e., UGTs and SULTs) represents the final step in the androgen metabolism. 
Androgens are then mainly excreted in urine (21, 22, 47, 48). The urinary androgen levels are 
dependent on the activity and expression of UGTs and SULTs and there are known 
polymorphisms in the genes coding for these enzymes associated with adult urinary androgen 
levels (21, 45, 181). Several fetal UGTs are expressed in the first trimester (234), it is therefore 
possible that genetic polymorphism in UGTs may be associated with the androgen load of the 
fetus during the first trimester, the time of pregnancy when the 2D:4D ratio is set (77, 78). 
Speculatively, genetic variations in genes coding for phase II enzymes could perhaps influence 
the development of the 2D:4D ratio and the predisposition for physical performance later in 
life and future studies could investigate this in a larger group.  
 
7.4 THE URINARY STEROID PROFILE IN FEMALE ELITE ATHELTES  
 
In female athletes, the interpretation of doping tests is complex possibly due to the impact of 
hormonal contraceptive use, hormonal fluctuations during the menstrual cycle, genetic 
variations affecting steroid metabolizing enzymes and exercise. It is therefore important to 
evaluate the effects of these factors on the urinary steroid profile.  
7.4.1 The impact of hormonal contraceptives and genetic variations on the 
urinary steroid profile 
We found that hormonal contraceptive use and genetic polymorphisms in UGT2B17 and 
CYP17 had an impact on the urinary steroid profile in female athletes. More specifically 
individuals with a deletion polymorphism in UGT2B17 excreted significantly lower T-G and 
had a lower T/E ratio compared to ins/del and ins/ins individuals. This is in line with previously 
published findings in men (21, 45). In an investigation including only four women, hormonal 
contraceptive use was found to affect the T/E ratio and suppression of EpiT levels were 
suggested as the mechanism behind these findings (68, 71). We could confirm this in a larger 
sample of female athletes (n=79), as we observed that female athletes using hormonal 
contraceptives had significantly lower EpiT-G levels and subsequently a higher T/E ratio. We 
noted similar findings in the separate populations of female Olympic athletes (n=94) and 
controls (n=86) included in study V. In a recently published interventional study the urinary 
steroid profile was examined in 55 regularly menstruating women, prior to and after three 
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months of using a COC containing levonorgestrel and ethinylestradiol (235).The authors found 
a decline in all urinary steroids included in the ABP although the largest decrease was observed 
for EpiT levels. Consequently, the T/E ratio increased. Taking this into account we considered 
the impact of hormonal contraceptives on the EpiT-G levels in women to be quite robust 
although it is possible that different hormonal contraceptives and COC types and the duration 
of treatment may result in varied EpiT responses.   
The production and metabolism of EpiT is largely unknown, although it has been suggested 
that EpiT is formed from pregnenolone by CYP17A1 (Figure 4). As mentioned in section 
3.2.1.1, a promotor region polymorphism (T>C exchange) in the CYP17A1 gene has been 
described. The CC variant is hypothesized to upregulate gene expression, and in men this 
variant has been associated with higher excretion of EpiT-G (45, 52). In female athletes using 
hormonal contraceptives we found similar results, with the CYP17A1 C-allele carriers having 
significantly higher EpiT-G and T-G levels compared to the TT genotype. In the previously 
mentioned intervention study by Ekström et al (235), it was noted that the HC induced changes 
in EpiT were associated with the CYP17A1 genotype, with individuals with a T-allele 
demonstrating a larger suppression of EpiT compared to individuals with a CC genotype. 
Among athletes not using hormonal contraceptives, we found no significant difference in EpiT 
levels depending on CYP17A1 genotype. A possible explanation and confounding factor being 
that in women not using hormonal contraceptives, EpiT levels seem to vary across the 
menstrual cycle with higher levels at ovulation and the luteal phase and higher T/E and 
5αAdiol/E ratios in the follicular phase (70, 188). Whereas in women using hormonal 
contraceptives, EpiT levels varied less (71). If urine samples had been collected in the same 
cycle phase for all participants, it is possible that the difference in EpiT levels depending 
CYP17A1 genotype may have been evident for hormonal contraceptive users as well.  
7.4.2 The urinary steroid profile in female athletes and controls  
To our knowledge, this is the first time a difference in urinary steroid profile between female 
athletes and sedentary controls has been demonstrated, with significantly lower urinary steroid 
metabolite levels observed in the athlete population. This difference was confirmed using both 
GC-MSMS (study V) and LC-MSMS (unpublished data). Similar findings have been described 
when comparing the urinary steroid metabolites between male athletes and controls (236). In 
the subgroup of athletes and controls not using hormonal contraceptives, comparable results 
were found. The lower urinary steroid levels observed in the athletes does not reflect the serum 
androgen levels. Indeed, no significant differences were observed between groups in T or DHT 
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and the precursor androgens DHEA and 5-DIOL were actually higher in the total population 
of female Olympic athletes compared to the control group.  
In women, the excretion of T is significantly higher in competition compared to out of 
competition and stress has been proposed as an influencing factor that may increase the 
excretion rate of urinary steroids (237). In our population of athletes and controls there were 
no significant differences in cortisol levels (a hormone that increases during stress). On the 
other hand, in the subgroup not using hormonal contraceptives, athletes actually had 
significantly higher cortisol levels compared to controls. Therefore, the influence of stress 
cannot likely explain the lower urinary steroid metabolites in the athletes. Other factors that 
may contribute to altered steroid profiles in women is genetic variations in especially 
UGT2B17. However, since the frequency of UGT2B17 del/del individuals were comparable 
between groups this should not have influenced our findings.  
A hypothetical explanation may be that androgens in athletes are also eliminated by additional 
routes e.g. in feces and/or sweat. In female athletes there are no studies investigating the 
excretion of steroids in feces. However, T and DHT were found to be highly abundant in feces 
from eight healthy men (44). Due to the lipophilic properties of steroids, sweat might also be a 
potential excretion route (43). It has been shown that steroid metabolites included in the ABP 
(A and T) can be excreted as sulphate conjugates in human axillary sweats (238). Additionally, 
after transdermal application of estr-4-ene diol, the metabolites nortestosterone and estr-4-
enedione were found in sweat collected after physical exercise (42). Therefore, one might 
speculate that the negative correlations between amount of training (hours per week) and 
certain urinary steroid metabolite concentrations may be due to alternative excretions routes 
such as sweat. However, further studies are needed to understand the association between 
training and urinary excretion rate of androgens in athletes. 
 
7.5 STRENGHTS AND LIMITATIONS  
 
In this thesis, we present novel findings on the associations between endogenous anabolic 
hormones, the 2D:4D ratio, body composition and physical performance in female Olympic 
athletes. We also provide results on the impact of hormonal contraceptives and genetic 
variations on the urinary steroid profile in a larger number of top female elite athletes. 
Additionally, we demonstrate for the first time, lower urinary androgen metabolite 
concentrations in female elite athletes compared to untrained controls.  
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The results presented in this thesis are of importance for the ongoing discussion regarding 
hyperandrogenism in women athletes. In fact, the results from study I were part of the research 
presented to and evaluated by CAS, leading to updated regulations concerning 
hyperandrogenism in women athletes in 2018. In addition, our results on the impact of 
hormonal contraceptives and genetics on the urinary steroid profile in female athletes may 
contribute to improving doping interpretation.  
Professor Angelica Lindén Hirschberg and associate professor Bo Berglund responsible for the 
research project are physicians at the SOC. Therefore, we were able to recruit such a unique 
study group i.e. female Olympic athletes. The recruitment was challenging due to the busy 
training and travelling schedule of the athletes and in the end, this led to recruitment taking 
several years (2011-2015). Some of the athletes were recruited at training camps, making it 
difficult for them to participate in the DXA examination and standardized physical 
performance tests at Bosön in Stockholm. Even so, we were able to recruit a large number of 
female Olympic athletes.  
In an effort to overcome potential confounding factors such as nutrition and effects of acute 
exercise/stress, that could theoretically influence circulating androgens, IGF-I and the urinary 
steroid profile blood and urine samples were collected in the morning in a rested and fasted 
state, for all participants. An additional strength of this thesis was that we analyzed the complete 
serum androgen profile by the golden standard method LC-MS/MS and the urinary steroid 
profile was determined by WADA accredited methods, GC-MS and GC-MS/MS at the 
accredited anti-doping Laboratory, Karolinska University Hospital, Huddinge.  
However, certain limitations should be addressed. Due to the cross-sectional study design 
casualty cannot be determined. Still, we believe that observational studies within this field can 
provide important knowledge, especially since the researcher is limited to the type of studies 
that can be performed in elite athletes. For example, supplementation of anabolic hormones 
would be highly unethical since these compounds are classified as doping agents.  
We were not able to take into account hormonal contraceptive use as well as the phase of the 
menstrual cycle as this would have been too challenging and result in fewer athletes being 
interested in participating in the studies. It has previously been reported that approximately 47 
% of female Swedish Olympic athletes use hormonal contraceptives (136). Furthermore, 
menstrual dysfunction is common among female elite athletes (134-136). Therefore, to only 
include female athletes not using hormonal contraceptives and with regular menstruation would 
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have resulted in significant selection bias and a reduced sample size, increasing the risk of type 
II error.  
Hormonal contraceptive use is known to affect serum T and SHBG levels (30, 139), whereas 
the impact on serum precursor androgens is less established (30, 140, 141). The influence of 
hormonal contraceptives on IGF-I levels is not fully elucidated. Estrogen therapies are 
suggested to alter the GH/IGF axis in women, the effects are dependent on type of estrogen, 
route of administration, duration of treatment and dose (116). However, the frequency of 
hormonal contraceptive use was comparable in our population of athletes and controls. 
Additionally, there were no statistically significant interactions between hormonal 
contraceptive use and endogenous androgens and IGF-I when comparing groups. When adding 
hormonal contraceptive use to the regression model in study I, we found no significant 
interaction and the reported correlations between lean mass and physical performance in the 
whole population of athletes were similar among athletes not using hormonal contraceptives. 
Also, in study III there were no significant differences in IGF-I or IGFSD depending on 
hormonal contraceptive use. Furthermore, in study V the differences in urinary steroid levels 
between athletes and controls were similar in the subgroup not using hormonal contraceptives. 
In the light of this, one can assume that the differences observed between groups and the 
significant correlations were not dependent on hormonal contraceptive use.  
Considering menstrual cycle phase, there is a small mid-cycle increase in T whereas previous 
investigations have found no significant variance in DHT, 5-DIOL DHEA and DHEAS levels 
across the menstrual cycle (4, 128-131). The variations in IGF-I levels during the menstrual 
cycle have been described to be none (119) or modest (117, 118) whereas unchanged levels 
have been reported for IGFBP-1 (117, 119). Therefore, even though blood samples were 
collected randomly during the menstrual cycle we do believe that the results presented are 
valid. Urinary androgen metabolite levels, especially EpiT fluctuates during the menstrual 
cycle (70). However, since doping tests are collected randomly, the results presented in study 
IV and V can provide valuable information.  
Athletes were divided into subgroups: power, endurance and technical as previously described 
(136). We do acknowledge the heterogeneity of sports included and that the limited number of 
athletes in each subgroup may have limited the ability to detect differences between sport 
categories.  
During the process of writing study III, an unintentional error was discovered regarding the 
height and weight of the athletes compared to controls. In study I, table 1, age, BMI, height and 
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weight of the athletes and controls were switched. The correct results are presented in this thesis 
and in study III. All original data and published findings were examined thoroughly, and no 
additional errors were found. Importantly, our main results were not affected by this mistake.  
In conclusion, even though certain limitations are evident we believe that the results presented 











8 CONCLUSION AND FUTURE DIRECTIONS  
 
8.1 CONCLUSION  
 
In conclusion, we observed higher precursor androgens and IGF-I levels in female Olympic 
athletes than in controls suggesting a more anabolic endocrine profile in the athletes. 
Furthermore, the lower 2D:4D ratio in the athletes compared to controls indicates a higher 
androgen exposure during fetal life in the athletes. Serum androgens and IGF-I levels were 
related to body composition, whereas both these anabolic hormones as well as the 2D:4D ratio 
were related to physical performance tests in the athletes.  Furthermore, in female athletes, 
hormonal contraceptive use and genetic polymorphism in UGT2B17 and CYP17 had an impact 
on the urinary Epi-T levels as well as the T/E ratio. Urinary androgen metabolite levels were 
significantly lower in female athletes compared to untrained controls and additionally, the 
metabolite levels were negatively associated with training hours per week in the athletes.  
8.1.1 Study specific conclusions  
I   The higher levels of endogenous precursor androgens (within the normal range) observed 
in female athletes compared to controls, and the significant correlations between 
androgens, lean mass and physical performance in the athletes, support a role of 
endogenous androgens in athletic performance in female athletes. 
II The lower 2D:4D ratio in female athletes than controls, and the association between a 
low 2D:4D ratio and physical performance tests in the athletes, suggest that a higher 
prenatal androgen exposure may be of importance for athletic capacity in female 
Olympic athletes. 
III  The higher endogenous IGF-I and IGFBP-1 levels observed in the athletes and the 
association with increased lean mass, lower fat percent and better SJ and squats 
performance may suggest that IGF-I and IGFBP-1 have an impact on body composition 
and physical performance in female athletes.  
IV Hormonal contraceptive use and UGT2B17 and CYP 17 polymorphisms affect the 
urinary steroid profile significantly, which should be considered in the evaluation of 




V Urinary androgen metabolites monitored in the ABP are lower in the female athletes than 
in untrained controls and negatively related to training hours per week in the athletes. 
However, serum androgen levels were comparable between groups. This may indicate a 
higher androgen metabolite excretion by alternative routes, such as feces and sweat in 
the female athletes.  
  
8.2 FUTURE DIRECTIONS  
 
This thesis sheds some light on the role of endogenous anabolic hormones in physical 
performance in female athletes and factors that have an impact on the urinary steroid profile in 
women.  
We found significant correlations between endogenous serum anabolic hormones, lean mass 
and physical performance. To further elucidate how circulating hormones affect physical 
performance in female athletes, it would be of great interest to study intracellular processes, 
such as the metabolism of DHEA and locally produced isoforms of IGF-I, in muscle tissue, an 
important organ in regard to explosive and strength performance.  
In the context of anti-doping testing, the quantification of endogenous serum steroids may be 
implemented as a complementary approach to the urinary steroid profile method in the future. 
Therefore, it would be of interest to study serum androgens and androgen metabolites 
longitudinally to evaluate intra-individual stability and the impact of different types of 
hormonal contraceptives and exercise in female elite athletes.  
We were intrigued by the unexpected finding of lower androgen metabolite levels in the female 
athletes compared to controls. We plan to investigate this further by studying different 
excretion routes after acute and chronic training in athletes and controls.  
It would also be of great interest to study the dose-response effect of exogenous anabolic 
hormones on physical performance. However, supplementation of T and/or GH/IGF-I cannot 
be performed in elite athletes but is theoretically possible in recreational female athletes under 
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